

Registration

[www.meeting-com.ch / Conferences & Meetings](http://www.meeting-com.ch/Conferences%20&%20Meetings)

Final
Program



50th Annual Meeting Swiss Society of Nephrology

Congress Centre Kursaal Interlaken
December 6-7, 2018

Schweizerische Gesellschaft für Nephrologie
Société Suisse de Néphrologie
Società Svizzera di Nefrologia

NEPHRO
SWISS SOCIETY OF NEPHROLOGY

www.swissnephrology.ch

Symposia

December 5, 2018

Basics in Nephrology

December 7, 2018

Pflege in der Nephrologie

Soins en Néphrologie

Cure in Nefrologia

Hands on

December 5, 2018

Hands-On Renal Ultrasound

Refreshment Course



Route de Moncor 10, 1752 Villars-sur-Glâne
List B. Full product information: www.swissmedicinfo.ch



Table of contents

Invitation 2018	4
Organization	5
General information	6
Program at a glance	9
Basics in Nephrology	12
Hands-On Renal Ultrasound Refreshment Course	13
Scientific Program	14
Congress Dinner	22
Scientific Program	24
Pflege in der Nephrologie	34
Poster presentations	36
Plan of exhibition	56
Exhibitors	57
Speakers / Moderators	58
Sponsored symposia in alphabetical order	59
Sponsors	60
SGN-SSN congress 2019	62

Invitation 2018

Dear Colleagues,

It is our great pleasure to invite you to the 50th annual meeting of the Swiss Society of Nephrology in Interlaken. For this commemorative meeting, we have introduced a series of new sessions, as well as special events.

On Wednesday, the CME will be organized by the Working Group on Nutrition. In addition, we are introducing a hands-on course on renal ultrasonography, free of charge but on a first-come first-served basis.

As to the main program, we followed your suggestions and increased the number of plenary lectures, covering the wide spectrum of nephrology. For this year: John Feehally (Past ISN President) will give us a historical and scientific overview on IgA Nephropathy; Tobias Huber (Hamburg) will take us on a fascinating journey about glomerulopathies; whereas Anna Köttgen (Freiburg) will discuss how genetic studies can help us to understand the normal and diseased kidney.

In the era of data science, we have introduced a special session on Swiss cohorts and registries, illustrating excellence of Swiss research in these fields. On Friday afternoon, the meeting will end with the popular session summarizing hot topics in nephrology in 2018.

Friday will also be dedicated to nurses-oriented sessions with talks from the three linguistic regions of Switzerland. We have selected themes which concern both nephrology nurses and nephrologists, such as resilience and transcultural competence.

We encourage you to attend the oral presentations and poster sessions, reflecting the vivid scientific activity of the Swiss nephrology community and the SSN members. The usual poster walk takes place on Thursday evening. Also, our industry partners have taken great care to support the society meeting and to sponsor symposia with high scientific value that should attract a wide audience.

This year, don't miss the special Friday morning ceremony awarding three honorary members for their outstanding contribution to adult and pediatric nephrology: Heini Murer, Bernard Rossier and Jean-Pierre Guignard. Last but not least, the group "Prima Carezza" will accompany us during the apero and gala dinner with salon music, prior to the dance floor after dinner.

We are looking forward to seeing you again in Interlaken.



Uyen Huynh-Do and Olivier Devuyst
Co-congress presidents SGN-SSN 2018

Organization

Congress Presidents

Uyen Huynh-Do, Bern
Olivier Devuyst, Zurich

Scientific Committee

Patrice Ambühl, Zurich	Andreas Kistler, Frauenfeld
Spiros Arampatzis, Bern	Johannes Loffing, Zurich
Isabelle Binet, St. Gallen	Eric Olinger, Zurich
Eric Feraille, Geneva	Belen Ponte, Geneva
Andreas Fischer, Lucerne	Stefan Schaub, Basel
Daniel Fuster, Bern	Stephan Segerer, Aarau
Luca Gabutti, Bellinzona	Dominik Uehlinger, Bern
Déla Golshayan, Lausanne	Grégoire Wuerzner, Lausanne
Min Jeong Kim, Aarau	

Board of the SGN-SSN

President 2018-2019

Uyen Huynh-Do, Bern

Past-President

Pierre-Yves Martin, Geneva

President-elect

Rudolf P. Wüthrich, Zurich

Secretary

Olivier Bonny, Lausanne

Treasurer

Patrick Wilson, Delémont

Pediatric Nephrologist

Thomas J. Neuhaus, Lucerne

Dialysis Commission

Dominik E. Uehlinger, Bern

Board Members

Isabelle Binet, St. Gallen
Andreas Bock, Aarau
Olivier Devuyst, Zurich
Daniel Fuster, Bern
Luca Gabutti, Bellinzona
Ann-Kathrin Schwarzkopf, Bern

General information

Congress venue

Congress Centre Kursaal Interlaken
Strandbadstrasse 44, 3800 Interlaken
www.congress-interlaken.ch

Registration & congress secretariat

Meeting-com Congress Organisation
Rue des Pâquis 1 • CP 100 • CH-1033 Cheseaux-sur-Lausanne
Online registration on : www.meeting-com.ch
T +41 21 312 9261 • F +41 21 312 9263 • E info@meeting-com.ch
Onsite registration also possible (onsite fee)

Registration fees for SGN congress

	Early bird fee (before Nov. 4, 2018)	Late fee (Nov. 5-Dec. 2, 2018)	Onsite fee (From Dec. 3, 2018)
Member SGN	CHF 230.00	CHF 270.00	CHF 300.00
NON-member SGN	CHF 280.00	CHF 320.00	CHF 360.00
Residents/Students*	CHF 150.00	CHF 180.00	CHF 210.00
Spezialisierte Pflege	CHF 100.00	CHF 120.00	CHF 150.00
NCCR-Member	CHF 150.00	CHF 180.00	CHF 210.00

The registration fee includes : access to the scientific sessions, congress documents and lunches. The Congress Dinner is not included and has to be booked separately when registering (CHF 90.00). Places are limited and a reservation is required.

*In order to benefit from the reduced fee, students or residents are required to send a document confirming their status to the SGN-SSN Congress Management by fax or scanned within 7 days from the date of registration.

Registration fees for Symposium 5.12.18

	Early bird fee (before Nov. 4, 2018)	Late fee (Nov. 5-Dec. 2, 2018)	Onsite fee (From Dec. 3, 2018)
Basics in Nephrology	CHF 100.00	CHF 120.00	CHF 150.00

Renal Ultrasound course for nephrologists – 13.00-15.00 – Theoretical update
free of charge – **open to all**
no registration needed

Hands on exercises – 15.30-17.30
free of charge – **limited places 16**
separate registration is required using the online-registration
on www.meeting-com.ch

General information

Payment

Upon registration you will receive a confirmation by email together with the banking details for the payment. Payment by credit card upon registration is possible.

Certificate of participation

The certificate of participation will be sent by secure PDF to all participant after the event

Cancellation

Written notification is required for all cancellations and changes. In case of cancellation 30 days prior the event, the refund of the amount paid will be done net of CHF 60.00 for administrative costs. Thereafter no refund possible. Any registration made within the “early bird” time must be paid during this period. If not the case, the invoice is automatically updated at the current price. Administrative costs will be charged to no shows. Legal jurisdiction is Lausanne.

Industrial exhibition

An industrial exhibition will take place at the Congress Venue. It will be open throughout the congress. Coffee (breaks) will be offered by exhibitors.

Hotel booking

Hotel reservation possible with Interlaken Tourismus on www.interlaken.ch.

WIFI

User ID 2638487096
Password 5031

Oral Presentations

The Scientific Committee will select a number of abstracts which will be presented as oral presentations.
[Speaking time : 8 min and 2 min discussion.](#)

Posters

The abstracts accepted as poster will be presented in the poster exhibition.
[Dimensions of posters : height 120 cm x width 90 cm \(portrait\).](#)

General information

Posterwalk

There will be an organized Posterwalk on Thursday, December 6, 2018, from 17 h 45 to 18 h 30 where the highest rated posters in each category will receive the Poster Prize Award:

- Basic Science / Genetics / Experimental Nephrology
- Transplantation
- Clinical Nephrology / Hypertension / Mineral / Electrolytes
- Hemodialysis (HD) / Peritoneal Dialysis (PD)

we thank each author to be present near his/her poster during the posterwalk

Poster Prize Awards

will take place during the Congress Dinner on December 6, 2018.

Registration

Authors presenting an accepted paper or poster must register and pay the appropriate registration fee.

Credits

Credits points will be given by the following societies:

SGN-SSN Congress, December 6-7, 2018

SGN-SSN	16 credits
SGAIM-SSMIG	in demand

Basics in Nephrology, December 5, 2018

SGN-SSN	4 credits
SGAIM-SSMIG	4 credits

Hands-On Renal Ultrasound Refreshment Course

SGN-SSN	2 credits for theoretical part
	2 credits for practical part

Language

Lectures in English, discussion in German, French or English.

The Symposium “Pflege in der Nephrologie” will be held in German, French and Italian

Program at a glance

Wednesday, December 5, 2018

	Special CME Symposium Basics in Nephrology Course	Hands-on Renal Ultrasound Refreshment Course
Schedule	Room A	Rooms Brünig and Susten
From 12.00	Registration	
13.00-15.00	Course	Theoretical Update (Room Brünig)
15.00-15.30	Coffee break	
15.30-17.30	Course	Hands-on exercises (Room Susten)
17.30-17.45	Conclusion	Final discussion & debriefing

Program at a glance

Thursday, December 6, 2018

Schedule	Room A	Room B
From 8.00	Registration	
09.45-09.50	Welcome Address	
09.50-10.45	State of the Art Lectures	
10.45-11.15	Coffee break – Visit of the exhibition – Poster viewing	
11.15-12.15	Oral Parallel Presentations Highlights of NCCR Kidney.CH Basic Science / Genetics / Experimental Nephrology	Oral Parallel Presentations Transplantation
12.15-12.30	Short break	
12.30-13.15	Exclusive Symposium Sponsored by VIFOR	
13.15-14.00	Lunch snacks in the exhibition – Poster viewing	
14.00-15.00	State of The Art Lectures	
15.00-15.30	Coffee break – Visit of the exhibition	
15.30-16.15	Exclusive Symposium Sponsored by ASTELLAS	
16.15-16.30	Short break	
16.30-17.30	Swiss Cohort & Registries	
17.45-18.30	Posterwalk in the Exhibition	
18.45	WELCOME DRINK & CONGRESS DINNER with Poster Prize Awards	

Program at a glance

Friday December 7, 2018

Schedule	Room A	Room B	Room Brünig
From 07.00	Registration		
07.45-09.15	General assembly SGN-SSN		
09.15-09.45	Honorary Members 2018		
09.45-10.30	Parallel Symposium Sponsored by ASTELLAS	Parallel Symposium Sponsored by AMGEN	10.00-10.45 Pflege in der Nephrologie
10.30-10.45	SGN-SSN Publication Award 2018		
10.45-11.15	Coffee break – Visit of the exhibition – Poster viewing		
11.15-12.00	State of the Art Lecture		11.15-13.15 Pflege in der Nephrologie
12.00-12.15	Short break		
12.30-13.15	Exclusive Symposium Sponsored by SANOFI & SANOFI GENZIME		
13.15-14.00	Lunch snacks – Visit of the exhibition – Poster viewing		
14.00-15.00	Oral Parallel Presentations Clinical Nephrology / Hypertension / Mineral / Electrolytes	Oral Parallel Presentations Hemodialysis (HD) / Peritoneal Dialysis (PD)	Pflege in der Nephrologie
15.00-15.30	Coffee break – Visit of the exhibition – Poster viewing		
15.30-16.30	Hot Topics and Updates 2018		15.30-17.00 Pflege in der Nephrologie
16.30	Farewell		

Satellite CME Symposium: Basics in Nephrology Nutrition – Sarcopenia – Bone Disease

From 12.00 Registration

Organisation

Working Group Nutrition Sarcopenia, Bone Disease of the SSN

Faculty and speakers

Prof. Dr. Daniel Teta, nephrologist, Sion

Prof. Dr. Bruno Vogt, nephrologist, Bern

PD Dr. Spyridon Arampatzis, nephrologist, Bern

Mrs Lorella Ciotto, renal dietitian, Sion

Dr. Thomas Hernandez, nephrologist, Geneva

Dr. Christian Bucher, nephrologist, St. Gallen

Dr. Argyrios Georgalis, nephrologist, Basel

Prof. Dr Laurence Genton, nutritionist, Geneva

Dr. Oliver Mauthner, PhD, advanced nursing practitioner, Basel

Scientific program

13.15 Welcome, introduction and learning objectives

13.30 A new look at low and very low protein diets to halt CKD progression

14.00 Tools and tricks to diagnose protein-energy wasting in dialysis patients

14.30 Prevention of protein-energy wasting and indications to nutritional support in dialysis patients

15.00-15.30 Coffee break

15.30 Nutritional management of nephrolithiasis

16.00 Screening and management of sarcopenia and frailty in CKD patients

16.30 Exercise and anabolic interventions in CKD

17.00 Gut microbiota as a new player in CKD

17.30 Conclusion and end of Basics in Nephrology Course

Hands-On Renal Ultrasound Refreshment Course

For nephrologistst in training

- A theoretical update on the indications and possibilities of renal ultrasound, open to all.
- Two hours of “hands on” exercises on volunteers and patients in small groups under the guidance of experienced sonographers, open to 16 principle “first come first served”. Possibility to subscribe in advance.
- Models to practice the placement of central lines and dialysis catheters.
By the end of the course, participants will be able to detect common and less common abnormalities of the native and transplant kidneys, measure renal resistive index, and will have updated their skills on US guided placement of central lines and kidney biopsies.

Organization SGN/SSN ultrasound commission

Key audience Any nephrologist (experienced or in training) who is interested in renal ultrasound can participate. Some basic experience is recommended, but not obligatory.

Instructors PD Dr Belen Ponte, PD Dr Spyridon Arampatzis, Dr Felix Burkhalter, PD Dr Menno Pruijm, Prof. Markus Mohaupt.

Language English

Costs free (first year)

Credits 2 for theoretical part, 2 for practical part

From 12.00 Registration

13.00-15.00 THEORETICAL UPDATE (no registration needed) Room Brünig

13.00-13.30 Introduction and Update renal US techniques (2D-Renal Resistive Index-CEUS-fibroscan)

Sypridon Arampatzis, Bern

13.30-14.00 Diagnostic pearls-native kidney

Menno Pruijm, Lausanne

14.00-14.30 Diagnostic pearls-transplant kidney

Felix Burkhalter, Bern

14.30-15.00 US-guided central line placement, AV fistula cannulation and renal biopsies

Belen Ponte, Genève

15.00-15.30 Coffee break

15.30-17.45 HANDS ON EXERCICES (limited to 16 places – registration mandatory) Room Susten

15.30-17.30 Practical exercises with healthy volunteers, patients and models

17.30-17.45 Final discussion and debriefing

Thursday, December 6

Swiss Society of Nephrology Congress

From 08.00	Registration	
09.45	Opening of the 50th Annual Meeting of the Swiss Society of Nephrology and Welcome Address Uyen Huynh-Do, Bern ; Olivier Devuyst, Zurich	Room A
09.50-10.45	State of The Art Lectures <i>Chair: Uyen Huynh-Do, Bern</i> 50 years IgA Nephropathy, from basic sciences to clinical trials John Feehally, Leicester (GB)	Room A
10.45-11.15	Coffee break – Visit of the exhibition – Poster viewing	Exhibition space
11.15-12.15	Oral Parallel Presentations <i>Chairs: Daniel Fuster, Bern ; Belen Ponte, Geneva</i>	
11.15-11.35	Highlights of NCCR Kidney.CH Carsten Wagner, Zurich	Room A
11.35-12.15	Basic Science / Genetics / Experimental Nephrology 4 oral presentations	
11.15-12.15	Transplantation <i>Chairs: Déla Golshayan, Lausanne ; Daniel Sidler, Bern</i> 6 oral presentations	Room B
12.15-12.30	Short break	

Oral communications

Oral Parallel Presentations

11.15-12.15	Basic Science / Genetics / Experimental Nephrology	Room A
	<i>Chairs: Daniel Fuster, Bern ; Belen Ponte, Geneva</i>	
OC 01	Transcriptional trajectories of human kidney disease progression Dr. Pietro Cippà¹ , Mr. Bo Sun ¹ , Dr. Jing Liu ¹ , Dr. Liang Chen ¹ , Dr. Maarten Naesens ² , Prof. Andrew McMahon ¹ ¹ University of Southern California, Los Angeles, USA ² University Hospitals Leuven, Leuven, Belgium	
OC 02	High magnesemia protects Memo1-deficient mice from calcification propensity Dr. Matthias Moor¹ , Dr. Suresh Ramakrishnan ¹ , Mrs. Finola Legrand ¹ , Dr. Matthias Bachtler ² , Prof. Robert Koesters ³ , Prof. Nancy Hynes ⁴ , Dr. Andreas Pasch ⁵ , Prof. Olivier Bonny ⁶ ¹ University of Lausanne, Lausanne, Switzerland, ² Calciscion, Nidau, Switzerland, ³ Université Pierre et Marie Curie, Paris, France, ⁴ Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland, ⁵ Inselspital Bern, Bern University Hospital, University of Bern, Bern, Switzerland, ⁶ CHUV and University of Lausanne, Lausanne, Switzerland	
OC 03	Primary Membranous Nephropathy: Potential novel biomarkers and therapeutic targets from glomerular RNA sequencing Mr. Øystein Eikrem ¹ , Dr. Nicolas Delaleu ² , Mr. Even Koch ³ , Dr. Thomas Knoop ¹ , Mr. Magnus Farstad ³ , Prof. Bjørn Egil Vikse ⁴ , Dr. Hanna Debiec ⁵ , Prof. Pierre Ronco ⁵ , Prof. Sabine Leh ¹ , Prof. Hans-Peter Marti¹ ¹ Haukeland University Hospital and University of Bergen, Bergen, Norway, ² 2CSysBioMed and Institute of Oncology Research, Bellinzona, Switzerland, ³ University of Bergen, Bergen, Norway, ⁴ Haugesund Hospital and University of Bergen, Bergen, Norway, ⁵ INSERM UMRS 1155, Paris, France	
OC 04	Pharmacokinetic and pharmacodynamic evaluation of a vascular calcification inhibitor (INS-3001) in rats Dr. Maillard Marc¹ , Dr. David Mordasini ¹ , Dr. Danny Spaggiari ² , Dr. Matthias Ivarson ³ , Dr. Roberto Maj ³ , Prof. Michel Burnier ¹ , Prof. Laurent Decosterd ² , Dr. Phan olivier ¹ ¹ Service of nephrology, Lausanne University Hospital, Lausanne, Switzerland, ² Service of clinical Pharmacology, Lausanne university, Lausanne, Switzerland, ³ Inositec AG, Zurich, Switzerland	

Oral communications

Oral Parallel Presentations

11.15-12.15

Transplantation

Chairs: Déla Golshayan, Lausanne; Daniel Sidler, Bern

Room B

- OC 05** **Pre-transplant detection of donor-specific B cell memory improves risk assessment for antibody-mediated rejection in sensitized renal allograft recipients**
Dr. Caroline Wehmeier¹, Dr. Gonca E. Karahan², Mrs. Juliette Krop², Mrs. Yvonne De Vaal², Mrs. Janneke Langerak-Langerak², Dr. Isabelle Binet³, Prof. Stefan Schaub¹, Dr. Dave L. Roelen², Prof. Frans H. J. Claas², Dr. Sebastiaan Heidt²
¹University Hospital Basel, Basel, Switzerland, ²Leiden University Medical Center, Leiden, Netherlands, ³Kantonsspital St. Gallen, St. Gallen, Switzerland
- OC 06** **Towards defining the Immunogenicity of HLA Epitopes: Impact of Eplets on Antibody Formation during Pregnancy**
 Prof. René Duquesnoy¹, Mrs. Marilyn Marrari¹, Mr. Matthias Niemann², Prof. Irene Hösl³, Prof. Stefan Schaub⁴, **Mr. Gideon Hönger**⁵
¹Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, USA, ²PIRCHE AG, Berlin, Germany, ³Department of Obstetrics and Fetomaternal Medicine, University Hospital Basel, Basel, Switzerland, ⁴Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland, ⁵Department of Biomedicine, Transplantation Immunology and Nephrology, University Basel, Basel, Switzerland
- OC 07** **CXCL10 measurement in late renal allograft biopsies predicts outcome even in histologically quiescent patients**
 Mrs. Joëlle Handschin¹, Dr. Caroline Wehmeier², Dr. Patrizia Amico², Dr. Helmut Hopfer³, Prof. Stefan Schaub², **Dr. Patricia Hirt-Minkowski**²
¹Transplantation Immunology and Nephrology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland, ²Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland, ³Institute for Pathology, University Hospital Basel, Basel, Switzerland

Oral communications

- OC 08** **Immune signatures of allograft rejection and outcome after kidney transplantation**
Dr. Josip Mikulic¹, Dr. Agnieszka Wojtowicz¹, Dr. Craig Fenwick¹, Prof. Giuseppe Pantaleo¹, Prof. Manuel Pascual¹, Prof. Dela Golshayan¹
¹CHUV and University of Lausanne, Lausanne, Switzerland
- OC 09** **Differential impact of delayed graft function in deceased donor renal transplant recipients with and without donor-specific HLA-antibodies**
Ms. Jana Haller¹, Dr. Caroline Wehmeier¹, Mr. Gideon Hönger¹, Dr. Patricia Hirt-Minkowski¹, Prof. Lorenz Gürke², Dr. Thomas Wolff², Prof. Jürg Steiger¹, Dr. Patrizia Amico¹, Prof. Michael Dickenmann¹, Prof. Stefan Schaub¹
¹Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland, ²Department of Vascular Surgery and Transplantation, University Hospital Basel, Basel, Switzerland
- OC 10** **Long-term outcome of DCD kidney transplantation**
 Mrs. Amelie Müller¹, **Dr. Kerstin Hübel**¹, Dr. Pietro Cippà¹, Mr. Jonas Ehrsam¹, Dr. Christian Oberkofler¹, Dr. Kuno Lehmann¹, Prof. Markus Weber², Prof. Thomas Müller¹, Prof. Philipp Dutkowski¹, Prof. Rudolf P. Wüthrich¹, Prof. Pierre-alain Clavin¹, Dr. Olivier De Rougemont¹
¹University Hospital of Zurich, Zurich, Switzerland, ²Triemlispital Zurich, Zurich, Switzerland

Management of Hyperkalemia in Cardio-renal Patients: what's new?

SGN/SSN Congress – Kursaal Interlaken
Thursday, December 6th, 2018, 12.30 – 13.15 h

Part I: Challenges and opportunities of potassium management in CKD and hypertension

Prof Patrick Rossignol (CHU Nancy, France)

Part II: Management of hyperkalemia in 2018: from bench to practice

Prof Patrick Saudan (HUG, Geneva)



Request the presentation slides

sgncongress@viforpharma.com or simply scan here:



This satellite symposium is sponsored by Vifor AG, Route de Moncor 10, 1752 Villars-sur-Glâne,
50th Annual Meeting of Swiss Society of Nephrology, Interlaken, December 6th – 7th, 2018

Thursday, December 6

12.30-13.15	Exclusive Symposium Sponsored by VIFOR  Room A
	MANAGEMENT OF HYPERKALEMIA IN CARDIO-RENAL PATIENTS: WHAT'S NEW?
Part I	Challenges and opportunities of potassium management in CKD and hypertension Patrick Rossignol, Nancy (F)
Part II	Management of hyperkalemia in 2018: from bench to practice Patrick Saudan, Geneva
13.15-14.00	Lunch snacks at the exhibition – Poster viewing Exhibition space
14.00-15.00	State of The Art Lecture <i>Chair: Olivier Devuyst, Zurich</i> Using genetic studies to understand kidney function in health and disease Anna Köttgen, Freiburg (DE) Room A
15.00-15.30	Coffee break – Visit of the exhibition – Poster viewing Exhibition space
15.30-16.15	Exclusive Symposium Sponsored by ASTELLAS  Room A <i>Chairs: Manuel Pascual, CHUV Lausanne; Jürg Steiger, USB Basel</i>
	Getting immunosuppression right
15.30	Welcome Manuel Pascual, CHUV, Lausanne; Jürg Steiger, USB, Basel
15.30	Minimal immunosuppression Stefan Schaub, USB, Basel
15.45	Treatment of late and chronic renal graft rejections Olivier Aubert, Inserm & Hôpital Necker, Paris (F)
16.10	Discussion & close Manuel Pascual, CHUV, Lausanne; Jürg Steiger, USB, Basel
16.15-16.30	Short break

Astellas Satellite Symposium – Renal Transplantation

Thursday, 6th of December 2018, 15:30–16:15, Saal A

Getting immunosuppression right

15:30 **Welcome**

Prof. Dr. med. Manuel Pascual, CHUV &
Prof. Dr. med. Jürg Steiger, USB

15:30 **Minimal immunosuppression**

Prof. Dr. med. Stefan Schaub, USB

15:45 **Treatment of late and chronic renal graft rejections**

Dr. med. Olivier Aubert
Inserm & Hôpital Necker, Paris

16:10 **Discussion & close**

Prof. Dr. med. Manuel Pascual, CHUV &
Prof. Dr. med. Jürg Steiger, USB

Thursday, December 6

16.30-17.30

Swiss Cohort & Registries

Room A

Chairs: Isabelle Binet, St. Gallen; Pierre-Yves Martin, Geneva

16.30-16.50

10 years STCS: excellence in transplantation research

Jürg Steiger, Basel

16.50-17.10

Swiss Systemic Lupus Cohort Study

Camillo Ribi, Lausanne

17.10-17.30

The Swiss Dialysis Registry: Demographic Trends

Patrice Ambühl, Zurich

17.45-18.30

Poster walk

Poster Area

Topics

– **Basic science / Genetics / Experimental Nephrology**

Jury

Olivier Bonny, Lausanne; Eric Feraille, Geneva

Topic

– **Transplantation**

Jury

Déla Golshayan, Lausanne; Patrizia Amico, Basel

Topics

– **Clinical Nephrology / Hypertension / Mineral / Electrolytes**

Jury

Min Jeong Kim, Aarau; Andreas Kistler, Frauenfeld

Topics

– **Hemodialysis (HD) / Peritoneal Dialysis (PD)**

Jury

Stephan Segerer, Aarau; Dominik Uehlinger, Bern

18.45

WELCOME DRINK & CONGRESS DINNER

Room B / Ballsaal

Poster Prize Awards

Thursday, December 6

Room B / Ballsaal

CONGRESS DINNER

18.45 **WELCOME DRINK & CONGRESS DINNER**
Poster Prize Awards



The magnificent rooms of the Casino Kursaal Interlaken date from the 19th century and provide a perfect setting for the Congress Dinner of the Swiss Society of Nephrology.

You will enjoy this unique atmosphere, combined with first-class service and excellent cuisine.

We await your reservation with pleasure when registering online on www.meeting-com.ch.
Pre-reservation is highly recommended. Additional tickets will be available at the registration desk on a first come first served basis.

Price: CHF 90.00/ticket (TTC)

Congress Centre Kursaal Interlaken – Strandbadstrasse 44 – 3800 Interlaken

50th Annual Meeting of the
Swiss Society of Nephrology SGN-SSN
Interlaken, Switzerland



Astellas Satellite Symposium
Friday, 7th December 2018,
09:45–10:30, Saal A

Optimal treatment of CKD anemia – Are we there yet?

09:45 **Welcome**
Prof. Dr. med. Rudolf P. Wüthrich, USZ &
PD Dr. med. Pietro Cippà, MD PhD, EOC Lugano

09:50 **Underlying pathophysiology revisited**
Prof. Dr. med. Sophie de Seigneux, MD PhD, HUG

10:05 **Current treatment and unmet medical needs**
Prof. Dr. med. Tilman B. Drüeke,
Inserm U1018, Hôp. Paul Brousse, Villejuif/Paris

10:25 **Discussion & close**
Prof. Dr. med. Rudolf P. Wüthrich, USZ &
PD Dr. med. Pietro Cippà, MD PhD, EOC Lugano

Friday, December 7

From 07.00

Registration

07.45-09.15

GENERAL ASSEMBLY SGN-SSN

Room A

09.15-09.45

Honorary Members 2018

Chairs: Uyen Huynh-Do, Bern; Thomas Neuhaus, Lucerne

09.15-09.25

Heini Murer, Zurich

09.25-09.35

Bernard Rossier, Lausanne

09.35-09.45

Jean-Pierre Guignard, Lausanne

09.45-10.30

Parallel Symposia

09.45-10.30

Parallel Symposium

Sponsored by **ASTELLAS**

Chairs: Rudolf. P. Wüthrich, USZ Zürich; Pietro Cippà, EOC Lugano



Room A

09.50

Underlying pathophysiology revisited

Sophie de Seigneux, HUG Geneva

10.05

Current treatment and unmet medical needs

Tilman B. Drüeke, Inserm & Hôpital Paul Brousse, Villejuif/Paris (F)

09.45-10.30

Parallel Symposium

Sponsored by **AMGEN**



Room B

Intravenous Calcimimetic: Shift to a New Standard of Care in sHPT

09.45-09.50

Introduction

Pierre-Yves Martin (Chair), Geneva

09.50-10.00

Recent advances in the management of sHPT

Olivier Phan, Lausanne

10.00-10.20

Learning from each other: first patient cases with Etelcalcetide

Daniel Hertner, Schwyz; Vincent Bourquin, Geneva

10.20-10.30

Interactive panel discussion

10.30-10.45

SGN-SSN Publication Award 2018

Chair: Olivier Devuyst, Zurich

Presentation and short address

Murielle Bochud, CHUV, Lausanne

Genome-Wide Meta-Analysis Unravels Interactions between Magnesium Homeostasis and Metabolic Phenotypes



Room A

10.45-11.15

Coffee break – Visit of the exhibition – Poster viewing

Exhibition space

INVITATION – PARALLEL SYMPOSIUM

Intravenous Calcimimetic: Shift to a New Standard of Care in sHPT

50th Annual Meeting of the Swiss Society of Nephrology SGN-SSN

December 7th 2018, 9:45–10:30

Congress Centre Kursaal Interlaken, Room B

09:45–09:50

Introduction

Prof. Pierre-Yves Martin (Chair)

Médecin-chef de service, HUG, Geneva

09:50–10:00

Recent advances in the management of sHPT

Dr. med. Olivier Phan

Médecin-associé, CHUV, Lausanne

10:00–10:20

Learning from each other:

first patient cases with Etelcalcetide

Dr. med. Daniel Hertner

Co-Chefarzt Innere Medizin, Spital Schwyz, Schwyz

Dr. med. Vincent Bourquin

Spécialiste en néphrologie, Hôpital de la Tour, Geneva

10:20–10:30

Interactive panel discussion



AMGEN Switzerland AG
Saurstoffli 22

CH-6343 Rotkreuz

© 2018 AMGEN. Rotkreuz, Switzerland.

Alle Rechte vorbehalten.

SC-CH-AMG416-00033



12:15 - 13:15

„New treatment trends, goals and fascinating cases in pre- and dialysis patients“

Plenum Room A

Chairman : Prof. Martin

12:15 - 12:55

„KDIGO guidelines – new treatment trends with calcium-free phosphate binders“

Prof. Pierre-Yves Martin - HUG

„Disruption of phosphate homeostasis: cases and lessons for the practice“

Prof. Olivier Bonny - CHUV

12:55 - 13:15

„Fabry disease and treatment goals in pre-dialysis patients“

Moderation: Prof. Uyen Huynh-Do, Inselspital Berne

Speaker: Prof. Robert J Desnick, PhD, MD Icahn School of Medicine at Mount Sinai, USA

Friday, December 7

11.15-12.00

State of The Art Lecture

Chair : Bruno Vogt, Bern

Glomerulopathies : From mechanism to disease

Tobias Huber, Hamburg (DE)

Room A

12.00-12.15

Short break

12.15-13.15

Exclusive Symposium

Sponsored by **SANOFI & SANOFI GENZYME**



Room A

NEW TREATMENT TRENDS, GOALS AND FASCINATING CASES IN PRE- AND DIALYSIS PATIENTS

Chair : Pierre-Yves Martin, HUG, Geneva

12.15-12.55

KDIGO guidelines – new treatment trends with calcium-free phosphate binders

Pierre-Yves Martin, HUG, Geneva

Disruption of phosphate homeostasis: cases and lessons for the practice

Olivier Bonny, CHUV, Lausanne

Chair : Uyen Huynh-Do, Inselspital Bern



12.55-13.15

Fabry disease and treatment goals in pre-dialysis patients

Robert J. Desnick, Icahn School of Medicine at Mount Sinai (USA)

13.15-14.00

Lunch snacks – Visit of the exhibition – Poster viewing

Exhibition space

14.00-15.00

Oral Parallel Presentations

14.00-15.00

Clinical Nephrology / Hypertension / Mineral / Electrolytes

Room A

Chairs : Ann-Kathrin Schwarzkopf, Bern ; Rudolf Wüthrich, Zurich

6 oral presentations

14.00-15.00

Hemodialysis (HD)/Peritoneal Dialysis (PD)

Room B

Chairs : Luca Gabutti, Bellinzona ; Patrick Wilson, Delémont

6 oral presentations

15.00-15.30

Coffee break – Visit of the exhibition - Poster viewing

Exhibition space

Oral communications

14.00-15.00

Clinical Nephrology / Hypertension / Mineral / Electrolytes

Room A

Chairs: Ann-Kathrin Schwarzkopf, Bern; Rudolf Wüthrich, Zurich

OC 11

Prospective evaluation of complex renal cystic lesions with contrast enhanced ultrasound (CEUS) and functional magnetic resonance imaging (MRI) versus the gold standard: computer tomography (CT)

Dr. Arampatzis Spyridon¹, Ms. Katarina Benackova², Dr. Dechen Wangmo Tshering Vogel³, Dr. Martin Müller⁴, Dr. Bernhard Kiss⁵, Prof. Fiona Burkhard⁵, Prof. George Thalman⁵, Prof. Johannes Heverhagen³, Prof. Dominik Uehlinger²

¹Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland, ²Department of Nephrology and Hypertension Inselspital, University Hospital, Bern, Switzerland, ³Department of Radiology, Neuroradiology and Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ⁴Department of Emergency Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ⁵Department of Urology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

OC 12

Estimated 24h Urinary Sodium and Sodium-to-Potassium Ratio are predictors of kidney function decline: a 5-year cohort study

Mr. Denis Deriaz¹, Prof. Idris Guessous², Prof. Peter Vollenweider³, Prof. Olivier Devuyst⁴, Prof. Michel Burnier⁵, Prof. Murielle Bochud⁶, **Dr. Belen Ponte**⁷

¹Institute of Social and Preventive Medicine, University Hospital of Lausanne, Lausanne, Switzerland, ²Division of Primary Care Medicine, University Hospital of Geneva, Geneva, Switzerland, ³Department of General Internal Medicine, CHUV and University of Lausanne, Lausanne, Switzerland, ⁴University Hospital of Zurich, Zurich, Switzerland, ⁵Service of nephrology, Lausanne University Hospital, Lausanne, Switzerland, ⁶IUMSP, CHUV, Lausanne, Switzerland, ⁷Division of Nephrology, University Hospital of Geneva, Geneva, Switzerland

Oral communications

OC 13

The Circular RNA ciRs-126 Predicts Survival in Critically Ill Patients with Acute Kidney Injury

Dr. Malte Kölling¹, Dr. Harald Seeger¹, Dr. George Haddad¹, Dr. Kistler Andreas², Dr. Albina Nowak¹, Dr. Robert Faulhaber-Walter³, Prof. Jan T. Kielstein³, Prof. Hermann Haller³, Prof. Danilo Fliser⁴, Prof. Thomas Müller¹, Prof. Rudolf P. Wüthrich¹, Prof. Johan M. Lorenzen¹

¹University Hospital of Zurich, Zurich, Switzerland, ²Frauenfeld Cantonal Hospital, Frauenfeld, Switzerland, ³Hannover Medical School, Hannover, Germany, ⁴Saarland University Medical Centre, Hombourg, Germany

OC 14

Quality of Life and Tolerability of Jinarc® (Tolvaptan) in Swiss ADPKD Patients

Dr. Manuel Anderegg¹, Dr. Nasser Dhayat¹, Dr. Mariam Semmo¹, Prof. Uyen Huynh-Do¹, Prof. Bruno Vogt¹, Prof. Daniel Fuster¹

¹Inselspital Bern, Bern University Hospital, University of Bern, Bern, Switzerland

OC 15

Short term- changes in dietary sodium intake influence muscle sodium content and sweat sodium concentration in healthy subjects

Dr. Philippe Braconnier¹, Mr. Nicolas Loncle¹, Mr. Joao Miguel Lourenco¹, Ms. Wendy Brito¹, Dr. Bastien Milani², Prof. Matthias Stuber², Prof. Michel Burnier¹, Dr. Menno Pruijm¹

¹Service of Nephrology and Hypertension, University Hospital of Lausanne, Lausanne, Switzerland, ²Service of Radiology, University Hospital of Lausanne, Lausanne, Switzerland

OC 16

Safety and Efficacy Study of Lumasiran (ALN-GO1), an Investigational RNA Interference (RNAi) Therapeutic, in Patients with Primary Hyperoxaluria Type 1

Dr. Tracy Mcgregor¹, Dr. Sally Hulton², Dr. Yaacov Frishberg³, Dr. Georges Deschenes⁴, Dr. Pierre Cochat⁵, Dr. Daniella Magen⁶, Dr. Jerome Harambat⁷, Dr. William Van't Hoff⁸, Dr. Bernd Hoppe⁹, Dr. John Lieske¹⁰, Dr. Patrick Haslett¹, Dr. David Erbe¹, Dr. Dawn Milliner¹⁰

¹Alnylam Pharmaceuticals, Cambridge, USA, ²Birmingham Childrens' Hospital, Birmingham, England, ³Shaare Zedek Medical Center, Jerusalem, Israel, ⁴Hospital Robert Debre/Pediatric Nephrology, Paris, France, ⁵Universite Claude Bernard Lyon, Villeurbanne, France, ⁶Rambam Health Care Campus, Haifa, Israel, ⁷Bordeaux University Hospital, Bordeaux, France, ⁸Great Ormond Street Hospital, London, England, ⁹University Hospital Bonn, Bonn, Germany, ¹⁰Mayo Clinic, Rochester, USA

Oral communications

14.00-15.00	Hemodialysis (HD)/Peritoneal Dialysis (PD)	Room B
	<i>Chairs: Luca Gabutti, Bellinzona; Patrick Wilson, Delémont</i>	
OC 17	Soluble CD146 and BNP dissect overhydration into functional components of prognostic relevance in hemodialysis patients Dr. Seraina von Moos ¹ , Dr. Mattia Arrigo ¹ , Mr. Kerem Gerritsen ¹ , £ Ms. Malha Saoune ² , Prof. Andrew Davenport ³ , Prof. Alexandre Mezabaa ² , Prof. Stephan Segerer ⁴ , Dr. Pietro Cippà ¹ ¹ Universitätsspital Zurich, Zurich, Switzerland, ² INSERM UMRS 942, Paris, France, ³ Royal Free Hospital, London, England, ⁴ Kantonsspital Aarau, Aarau, Switzerland	
OC 18	Dialysis after graft loss: the Swiss experience Dr. Marco Bonani ¹ , Ms. Rita Achermann ² , Dr. Harald Seeger ¹ , Dr. Michael Scharfe ³ , Prof. Thomas Müller ¹ , Prof. Stefan Schaub ⁴ , Dr. Isabelle Binet ⁵ , Prof. Uyen Huynh-Do ⁶ , Dr. Suzan Dahdal ⁶ , Prof. Dela Golshayan ⁷ , Dr. Karine Hadaya ⁸ , Prof. Rudolf P. Wüthrich ¹ , Prof. Fehr Thomas ⁹ , Prof. Stephan Segerer ¹⁰ ¹ University Hospital of Zurich, Division of Nephrology, Zurich, Switzerland, ² University Hospital Basel, Department Transplant Immunology and Nephrology, Basel, Switzerland, ³ University Hospital Basel, Department of Clinical Research, Basel, Switzerland, ⁴ University Hospital Basel, Basel, Switzerland, ⁵ Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁶ Inselspital Bern, Bern University Hospital, University of Bern, Switzerland, ⁷ CHUV University Hospital Lausanne, Transplantation Center, Lausanne, Switzerland, ⁸ Geneva University Hospitals, Nephrology and Transplantation, Geneva, Switzerland, ⁹ Kantonsspital Graubünden, Department of Internal Medicine, Graubünde, Switzerland, ¹⁰ Division of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Aarau, Switzerland	
OC 19	Hospitalizations within the first year and survival in patients aged below and above 80 who start dialysis in emergency Dr. Cyrielle Alves ¹ , Dr. Thomas Hernandez ² , Dr. Sebastian Carballo ³ , Prof. Pierre-Yves Martin ⁴ , Prof. Patrick Saudan ² ¹ Geneva University Hospital, Geneva, Switzerland, ² HUG, Geneva, Switzerland, ³ Geneva University Hospital, Internal Medicine, Geneva, Switzerland, ⁴ University Hospital of Geneva, Geneva, Switzerland	

Oral communications

OC 20	DIALFIT: Water-soluble vitamins in chronic on-line hemodiafiltration patients Dr. Nora Schwotzer ¹ , Dr. Michiko Kanemitsu ¹ , Prof. Roger Darioli ² , Dr. Sebastien Kissling ¹ , Prof. Michel Burnier ¹ , Dr. Menno Pruijm ³ ¹ Service of nephrology, Lausanne University Hospital, Lausanne, Switzerland, ² Swiss Vitamin Institute, Epalinges, Switzerland, ³ CHUV, Lausanne, Switzerland
OC 21	Incidence and prevalence of home dialysis treatment in the Swiss dialysis population between 2013 and 2017 Dr. Jennifer Scotti Gerber ¹ , Dr. Davide Giunzioni ¹ , Dr. Giulia Bedino ¹ , Dr. Marianna De Francesco ¹ , Dr. Alberto Pagnamenta ² , Dr. Carlo Schoenholzer ¹ ¹ Ospedale Regionale di Lugano, Lugano, Switzerland, ² Ospedale Regionale di Mendrisio, Mendrisio, Switzerland
OC 22	The effectiveness and safety of regional citrate anticoagulation in high cut off hemodialysis among patients with myeloma cast nephropathy Dr. Sebastien Kissling ¹ , Mr. Luc Sarrasin ² , Prof. Daniel Teta ³ , Dr. Menno Pruijm ⁴ ¹ Service of nephrology, Lausanne University Hospital, Lausanne, Switzerland, ² Université de Lausanne, Lausanne, Switzerland, ³ Kantonsspital Valais, Sion, Switzerland, ⁴ CHUV, Lausanne, Switzerland

Friday, December 7

15.30-16.30 **Hot Topics and Updates 2018**
Chairs: Olivier Devuyst, Zurich; Andreas Bock, Aarau

15.30-15.50 **Basic Sciences**
 Sophie de Seigneux, Geneva

15.50-16.10 **General Nephrology**
 Grégoire Wuerzner, Lausanne

16.10-16.30 **Transplantation**
 Stefan Schaub, Basel

Room A

16.30 **Farewell**
 Olivier Devuyst, Zurich; Uyen Huynh-Do, Bern

Room A



Endlich! Licht in Sicht bei ADPKD.

JINARC® – Die erste krankheitsmodifizierende Therapie für Patienten mit autosomal-dominanter polyzystischer Nierenerkrankung (ADPKD)* 1,2

- reduziert die Zunahme des Nierenvolumens¹
- verlangsamt die Abnahme der renalen Funktion¹
- mindert das Risiko von ADPKD-assoziierten Schmerzen¹

* Ausführliche Informationen zur Kassenzulässigkeit entnehmen Sie bitte der Spezialitätenliste unter www.spezialitaetenliste.ch
 * Erwachsene mit chronischer Nierenerkrankung (CKD) im Stadium 1 bis 3 zu Behandlungsbeginn mit Anzeichen für rasch fortschreitende Erkrankung²

Referenzen:
 1. Torres VE, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407–2418.
 2. Fachinformation Jinarc®: www.swissmedicinfo.ch



Jinarc® (Tolvaptan) Kurzfachinformation. Indikation: Verlangsamung der Progression von Zystenentwicklung und Niereninsuffizienz bei autosomal-dominanter polyzystischer Nierenerkrankung (ADPKD) bei Erwachsenen mit chronischer Nierenerkrankung (CKD) (Stad. 1 - 3 zu Behandlungsbeginn) mit Anzeichen für rasch fortschreitende Erkrankung. **Dosierung:** 2 x täglich als geteilte Dosis von 45 mg + 15 mg (Anfangsdosis), Dosistherapie auf 60 mg + 30 mg oder 90 mg + 30 mg. Die Patienten müssen die höchste verträgliche Dosis Tolvaptan erhalten. Die Tolvaptan-Therapie darf nur von Ärzten eingeleitet und beaufsichtigt werden, die Erfahrung in der Behandlung von ADPKD haben und denen die Risiken einer Tolvaptan-Behandlung einschliesslich der Hepatotoxizität sowie die notwendigen Überwachungsmassnahmen vollumfänglich bekannt sind. **Kontraindikation:** Überempfindlichkeit gegen den Wirkstoff oder sonstige Bestandteile; erhöhte Leberenzyme u./o. Anzeichen oder Symptome einer Leberschädigung vor der Einleitung der Behandlung, die die Anforderungen für ein dauerhaftes Absetzen von Tolvaptan erfüllen; Volumendepletion; Hyponatriämie; Anurie; Patienten, die Durst nicht wahrnehmen, oder auf Durst nicht reagieren können; Schwangerschaft; Stillzeit. **Warnhinweise und Vorsichtsmassnahmen:** Tolvaptan wurde mit idiosynkratischen Zunahmen der Alanin- und Aspartat-Aminotransferase (ALT und AST) Spiegel und in seltenen Fällen mit einer gleichzeitigen Erhöhung des Gesamtbilirubins (BT) in Verbindung gebracht. Um das Risiko von erheblichen und/oder irreversiblen Leberschäden zu verringern, sind Bluttests zur Bestimmung der Lebertransaminasen und des Bilirubins vor Beginn der Behandlung mit Jinarc, danach monatlich für 18 Monate und danach regelmässig alle 3 Monate erforderlich. Die gleichzeitige Überwachung auf Symptome, die auf Leberschäden hinweisen können (wie Müdigkeit, Appetitlosigkeit, Übelkeit, Beschwerden im rechten Oberbauch, Erbrechen, Fieber, Hautausschlag, Juckreiz, dunkler Urin oder Gelbsucht), wird empfohlen. Dehydrierung, Harnausflussobstruktion, Flüssigkeits- und Elektrolythaushalt, abnormale Serumtransaminaspiegel, Anaphylaxie, Diabetes mellitus, erhöhte Harnsäurewerte, CYP3A- und P-gp-Induktoren. **Interaktionen:** Mässige oder starke CYP3A-Inhibitoren; starke CYP3A- und P-gp-Induktoren; CYP3A-, CYP2C9-, P-gp- und Transporter-Substrate; Diuretika oder nicht diuretische Anthypertensiva; Vasopressin-Analoga. **Unerwünschte Wirkungen: sehr häufig:** Polydipsie, Kopfschmerzen, Schwindel, Durchfall, Mundtrockenheit, Nykturie, Pollakisurie, Polyurie, Müdigkeit, Durst; **häufig:** Dehydratation, Hyponatriämie, verminderter Appetit, Hyperurikämie, Hyperglykämie, Schlaflosigkeit, Herzklopfen, Dyspnoe, Blähungen, Verstopfung, Dyspepsie, gastroösophageale Refluxkrankheit, gestörte Leberfunktion, Exanthem, Juckreiz, Muskelkrämpfe, Asthenie, erhöhte Alanin-Aminotransferase, erhöhte Aspartat-Aminotransferase, Gewichtsabnahme. **Packungen:** 28 Tabletten: 15, 30 mg Tolvaptan. 56 Tabletten: 28 x 45 mg + 28 x 15 mg Tolvaptan. 56 Tabletten: 28 x 60 mg + 28 x 30 mg Tolvaptan. 56 Tabletten: 28 x 90 mg + 28 x 30 mg Tolvaptan. Konsultieren Sie bitte vor einer Verschreibung die vollständige Fachinformation, die auf der Homepage von Swissmedic unter www.swissmedicinfo.ch publiziert ist. **Abgabekategorie:** A, **Zulassungsinhaber:** Otsuka Pharmaceutical (Switzerland) GmbH, Sägereistrasse 20, 8152 Glattbrugg. **Stand:** August 2017 (v002).

Friday, December 7

Special Satellite Symposium

Room Brünig

Pflege in der Nephrologie / Soins en Néphrologie / Cure in Nefrologia

Sprache: deutsch (Slides und Fragen: auch auf französisch und italienisch)

Vorsitz: Claudia Studer, Zürich; Irma König, Bellinzona; Ursula Dietrich, Bern

10.00-10.15	Begrüssung
10.15-10.45	50 Jahre SGN Vergangenheit und Zukunft der Hämodialysebehandlung Ute Helt, Leiterin pflege, Institut für Nephrologie, Stadtspital Waid Zürich

10.45-11.15 Pause Room Brünig

11.15-12.15	Resilienz? Was ist das? Wie kann ich das für mich und meine PatientInnen nutzen? Franziska Heigl, Msc, Leitende Ergotherapeutin und Therapie-Expertin, Universitätsklinik für Rheumatologie, Immunologie und Allergologie, Inselspital Bern
12.15-12.45	Nefrologia EOC: In Progetto comune: Presa a carico dei pazienti in ambulatorio Lazarevic Predrag, Caporeparto Infermieristico Dialisi; Tartaglia Francesca, Infermiera Dialisi EOC – Ospedale regionale di Bellinzona e Valli
12.45-13.15	L'adhésion non médicamenteuse et la perception de la maladie chez des patients hémodialisés: une étude descriptive corrélationnelle Burnier Michel, Professeur honoraire à l'UNIL, Lausanne Delmas Philippe, Professeur ordinaire HES-SO, Institut et Haute école de la santé La Source Lausanne Behaghel Ghislaine, Infirmière Clinicienne Spécialisée, Service de Soins palliatifs et de support CHUV, Lausanne

13.15-14.00 Lunch snacks – Visit of the exhibition – Poster viewing Exhibition space

Friday, December 7

Special Satellite Symposium

Room Brünig

14.00-14.30	Entwicklung von Informationsmaterial für Patientinnen und Patienten, die mit einem zentralvenösen Dialysekatheter zu Hause leben Sabine Herzig, Pflegeexpertin, Masterstudentin Pflegewissenschaften, Universitätsklinik für Nephrologie und Hypertonie, Inselspital Bern
14.30-15.00	Convivere con il paziente «difficile» in nefrologia/dialisi Nicola Grignoli, Servizio di psichiatria e psicologia medica OSC e Fondazione Sasso Corbaro; Giovanni Isella, Caporeparto Infermieristico Emodialisi, EOC-Ospedale regionale di Lugano

15.00-15.30 Coffee break – Visit of the exhibition - Poster viewing Exhibition space

15.30-16.45	Transkulturelle Kompetenz Claudia Schönbächler, MAS Transkulturelle Kommunikation und Management Kommission für Diversität, Universitäts-Kinderspital Zürich
16.45-17.00	Verabschiedung Claudia Studer, Zürich; Irma König, Bellinzona; Ursula Dietrich, Bern

Poster presentations

P 01 – P 14 **Basic Science / Genetics / Experimental Nephrology**
P 15 – P 29 **Transplantation**
P 30 – P 59 **Clinical Nephrology / Hypertension / Mineral / Electrolytes**
P 60 – P 73 **Hemodialysis / Peritoneal Dialysis**

Basic Science / Genetics / Experimental Nephrology

- P 01** **Late B lymphocyte action in dysfunctional tissue repair following kidney injury and transplantation**
Dr. Pietro Cippà¹, Dr. Jing Liu¹, Mr. Bo Sun¹, Dr. Sanjeev Kumar¹, Dr. Maarten Naesens², Prof. Andrew McMahon¹
¹University of Southern California, Los Angeles, USA, ²University Hospitals Leuven, Leuven, Belgium
- P 02** **Regulation of Klotho by proteinuria in Chronic Kidney Disease**
Ms. Vasiliki Delitsikou¹, Ms. Frédérique Ino¹, Mr. George Jarad², Mr. Jeffrey Miner², Prof. Feraille Eric¹, Prof. Sophie De Seigneux³
¹University of Geneva, Geneva, Switzerland, ²Washington University School of Medicine, Washington, USA, ³University Hospital of Geneva, Geneva, Switzerland
- P 03** **Tissue proteome profiling of hypoxic fetal kidneys reveals pathological changes associated with inflammation and aging**
Dr. Stefan Rudloff¹, Dr. Andrea Bileck¹, Mr. Lukas Janker², Prof. Uyen Huynh-Do¹, Prof. Christopher Gerner²
¹Department of Nephrology and Hypertension, University Hospital Bern and Department for BioMedical Research, University of Bern, Bern, Switzerland, ²Department of Analytical Chemistry, University of Vienna, Vienna, Austria
- P 04** **Mice deleted for cystathionine-gamma-lyase are protected from calcium oxalate nephropathy**
Dr. Yimin Lu¹, Dr. Suresh Ramakrishnan¹, Dr. Muriel Auberson¹, Ms. Fanny Durussel¹, Prof. Isao Ishii², Prof. Olivier Bonny³
¹University of Lausanne, Lausanne, Switzerland, ²Showa Pharmaceutical University, Tokyo, Japan, ³CHUV and University of Lausanne, Lausanne, Switzerland

Poster presentations

- P 05** **Glucocorticoids affect steroid metabolome and concentration of galactose deficient IgA in patients with IgA nephropathy**
Prof. Milan Raska¹, Dr. Petr Kosztu¹, Dr. Martin Hill², Dr. Leona Raskova Kafkova¹, Ms. Lydie Czernekova¹, Dr. Miroslav Hruby³, Prof. Karel Matousovic⁴, Dr. Karel Vondrak⁵, Prof. Josef Zadrazil³, Prof. Ivan Sterzl², Prof. Jiri Mestecky⁶
¹Department of Immunology, Faculty of Medicine and Dentistry, Palacky University, Olomouc and University Hospital Olomouc, Olomouc, Czech Republic, ²Department of Steroids and Proteohormones and Department of Clinical Immunology, Institute of Endocrinology, Prague, Czech Republic, ³Department of Internal Medicine III Nephrology, Rheumatology and Endocrinology, Palacky University Olomouc, Olomouc, Czech Republic, ⁴Department of Medicine, Second School of Medicine, Charles University, Prague and University Hospital Motol, Prague, Czech Republic, ⁵Department of Pediatrics, Second School of Medicine, Charles University, Prague and University Hospital Motol, Prague, Czech Republic, ⁶Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
- P 06** **Mechanism of sodium retention in a genetic mouse model of nephrotic syndrome (NCCR project)**
Dr. Valérie Olivier¹, Dr. Eva Dizin¹, Ms. Charline Maire¹, Dr. Khalil Udwan¹, Prof. Johannes Loffing², Dr. Joseph Rutkowski³, Prof. Sophie De Seigneux¹, Dr. MAILLARD Marc⁴, Prof. Aurélie Edwards⁵, Prof. Feraille Eric¹
¹University of Geneva, Geneva, Switzerland, ²University Hospital of Zurich, Zurich, Switzerland, ³ATM college of medicine, Bryan, Texas, USA, ⁴Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ⁵Boston University, Boston, USA
- P 07** **Coupling between paracellular and transcellular ion transport in renal collecting duct**
Dr. Ali SASSI¹
¹Geneva, Switzerland
- P 08** **Molecular Pathways of Calcineurin Inhibitor Toxicity in the Kidney**
Ms. Andrea Karolin¹, Dr. Sofia Verouti¹, Dr. Stefan Rudloff¹, Dr. Geneviève Escher¹, Dr. Daniel Sidler²
¹Department of Nephrology and Hypertension, Inselspital, and Department for BioMedical Research, University of Bern, Bern, Switzerland, ²Inselspital Bern, Bern University Hospital, University of Bern, Switzerland

Poster presentations

- P 09** **The Effect of Dietary Amino Acids on Chronic Kidney Disease Progression in Rats (NCCR project)**
Dr. Samyuktha Pillai¹, Dr. Giovanni Pellegrini¹, Prof. François Verrey¹
¹University of Zurich, Zurich, Switzerland
- P 10** **A mouse model of renal calcium oxalate crystallopathy**
Dr. Yimin Lu¹, Dr. Suresh Ramakrishnan¹, Dr. Muriel Auberson¹, Ms. Fanny Durussel¹, Prof. Olivier Bonny²
¹University of Lausanne, Lausanne, Switzerland ²CHUV and University of Lausanne, Lausanne, Switzerland
- P 11** **Proregenerative role of long non-coding RNA H19 in ischemic acute kidney injury**
Dr. George Haddad¹, Dr. Malte Kolling¹, Prof. Rudolf P. Wüthrich², Prof. Johan M. Lorenzen²
¹University of Zurich, Zurich, Switzerland, ²University Hospital of Zurich, Zurich, Switzerland
- P 12** **Effects of various thiol derivatives on a calcium oxalate crystallopathy mouse model**
Dr. Yimin Lu¹, Dr. Suresh Ramakrishnan², Dr. Muriel Auberson², Ms. Fanny Durussel², Prof. Olivier Bonny¹
¹CHUV and University of Lausanne, Lausanne, Switzerland, ²University of Lausanne, Lausanne, Switzerland
- P 13** **A patient with Very large Nuclei**
Dr. Jonathan Dash¹, Prof. Patrick Saudan¹, Dr. Solange Moll¹, Prof. Sophie De Seigneux²
¹HUG, Geneva, Switzerland, ²University Hospital of Geneva, Geneva, Switzerland
- P 14** **Fabry Disease: Incidence of Pathogenic GLA Mutations Estimated by Newborn Screening Studies**
Dr. Albina Nowak¹, Prof. Robert Desnick²
¹University Hospital of Zurich, Zurich, Switzerland, ²Icahn School of Medicine at Mount Sinai, New York, USA

Poster presentations

Transplantation

- P 15** **Preformed Donor-reactive T-cells That Persist After ABO Desensitization Independently Predict Severe Acute Cellular Rejection After Living Donor Kidney Transplantation**
Dr. Thomas Schachtner¹, Dr. Natalie Otto², Prof. Petra Reinke²
¹University Hospital of Zurich, Zurich, Switzerland, ²Charite University Medicine Berlin, Berlin, Germany
- P 16** **Kidney Re-transplantation after Graft Failure: a Single Center Experience**
Mr. Jonas Ehrsam¹, **Dr. Kerstin Hübel¹**, Prof. Thomas Müller¹, Dr. Olivier De Rougemont¹
¹University Hospital of Zurich, Zurich, Switzerland
- P 17** **Revisiting cytomegalovirus sero-status and infection as risk factors in the current era of renal transplantation**
Ms. Nicole Bischof¹, Ms. Klaudia Nägele², Dr. Caroline Wehmeier¹, Dr. Patricia Hirt-Minkowski¹, Dr. Patrizia Amico¹, Prof. Michael Dickenmann¹, Prof. Hans Hirsch², Prof. Stefan Schaub¹
¹Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland, ²Transplantation and Clinical Virology, Department of Biomedicine (Haus Petersplatz), University of Basel, Basel, Switzerland
- P 18** **Serum bicarbonate levels are associated with graft survival and mortality in kidney transplant recipients in Switzerland**
Ms. Anna Wiegand¹, Ms. Sandar F. Lim², Prof. Rudolf P. Wüthrich¹, Prof. Leonhard Held², Dr. Nilufar Mohebbi¹
¹University Hospital of Zurich, Zurich, Switzerland, ²University of Zurich, Zurich, Switzerland
- P 19** **Effect of Denosumab on Trabecular Bone Score in de novo Kidney Transplant Recipients**
Dr. Marco Bonani¹, Dr. Diana Frey², Dr. Nicole Graf³, Prof. Rudolf P. Wüthrich⁴
¹University Hospital Zurich, Division of Nephrology, Zurich, Switzerland, ²University Hospital Zurich, Division of Rheumatology, Zurich, Switzerland, ³Graf Biostatistics, Winterthur, Switzerland, ⁴University Hospital of Zurich, Division of Nephrology, Zurich, Switzerland

Poster presentations

- P 20** **Follow-up of bone mineral density changes in de novo kidney transplant recipients treated with two doses of the RANKL inhibitor denosumab**
Dr. Claudia Kobel¹, Dr. Diana Frey², Dr. Nicole Graf³, Prof. Rudolf P. Wüthrich⁴, Dr. Marco Bonani⁴
¹University Hospital Zurich, Division of Nephrology, Zurich, Switzerland, ²University Hospital Zurich, Division of Rheumatology, Zurich, Switzerland, ³Graf Biostatistics, Winterthur, Switzerland, ⁴University Hospital of Zurich, Division of Nephrology, Zurich, Switzerland
- P 21** **Preservation of kidney function in kidney transplant recipients by alkali therapy (Preserve-Transplant Study)**
 Ms. Anna Wiegand¹, **Dr. Alexander Ritter**¹, Dr. Nicole Graf², Dr. Spyridon Arampatzis³, Dr. Daniel Sidler³, Dr. Karine Hadaya⁴, Prof. Thomas Müller¹, Prof. Carsten Wagner⁵, Prof. Rudolf P. Wüthrich¹, Dr. Nilufar Mohebbi¹
¹University Hospital of Zurich, Division of Nephrology, Zurich, Switzerland, ²Graf Biostatistics, Winterthur, Switzerland, ³Inselspital Bern, Division of Nephrology, Bern, Switzerland, ⁴Geneva University Hospitals, Division of Nephrology and Transplantation, Geneva, Switzerland, ⁵University of Zurich, Institute of Physiology, Zurich, Switzerland
- P 22** **Two Decades of Kidney Transplantation in the Elderly: The Gender Gap in Mortality Impacts Patient Survival After Kidney Transplantation**
Dr. Thomas Schachtner¹, Dr. Natalie Otto², Prof. Petra Reinke³
¹University Hospital of Zurich, Zurich, Switzerland, ²Charite, Berlin, Germany, ³Charite University Medicine Berlin, Berlin, Germany
- P 23** **Ethical evaluation before living kidney donation: a monocentric pilot study**
Dr. Karine Hadaya¹, Mrs. Monique Lamuela Naulin², Dr. Monica Escher Imhof³, Prof. Christophe Iselin⁴, Prof. Thierry Berney⁵, Prof. Pierre-Yves Martin⁶, Prof. Bara Ricou³
¹Geneva University Hospitals, Nephrology and Transplantation, Geneva, Switzerland, ²Geneva University Hospitals, Gynecology and Obstetrics, Geneva, Switzerland, ³Geneva University Hospitals, Pharmacology and Intensive Care, Geneva, Switzerland, ⁴Geneva University Hospitals, Urology, Geneva, Switzerland, ⁵Geneva University Hospitals, Transplantation, Geneva, Switzerland, ⁶University Hospital of Geneva, Geneva, Switzerland

Poster presentations

- P 24** **Severe West-Nile meningoencephalitis in a recent renal transplant recipient: a case report**
Dr. Andreea Moldovan¹, Dr. Ioana Varga², Dr. Mihaela Verzan³, Prof. Christian Van Delden⁴, Dr. Vlad Untaru⁵, Dr. Bogdan Moldovan⁶, Dr. Karine Hadaya⁷
¹St Constantin Hospital, Division of Infectious Disease, Brasov, Romania, ²St Constantin Hospital, Division of Neurology, Brasov, Romania, ³St Constantin Hospital, Division of Nephrology, Brasov, Romania, ⁴Geneva University Hospitals, Division of Infectious Disease, Geneva, Switzerland, ⁵St Constantin Hospital, Division of Intensive Care, Brasov, Romania, ⁶St Constantin Hospital, Division of Surgery, Brasov, Romania, ⁷Geneva University Hospitals, Nephrology and Transplantation, Geneva, Switzerland
- P 25** **Allograft dysfunction in patients with progressive atherosclerotic disease of the common iliac artery: a case series**
Dr. Sandra Knych¹, Dr. Stefan Kalbermatter¹, Dr. Patrick Nussbaumer², Dr. Damien Toia³, Dr. Andrej Isaak⁴, Dr. Felix Burkhalter¹
¹Division of Nephrology, Kantonsspital Baselland, Liestal, Switzerland, ²Division of Angiology, Kantonsspital Baselland, Liestal, Switzerland, ³Division of Radiology, Kantonsspital Baselland, Liestal, Switzerland, ⁴Department of Vascular Surgery and Transplantation, University Hospital Basel, Basel, Switzerland
- P 26** **Prediction of allocation date in deceased donor transplantation. A retrospective single center experience**
Ms. Nicole Yacob¹, Mr. Fabian Hauenstein¹, Dr. Suzan Dahdal¹, Dr. Daniel Sidler¹
¹Inselspital Bern, Bern University Hospital, University of Bern, Switzerland
- P 27** **Preliminary results of the STCS Renal Allograft Twin Study**
Mrs. Sanda Branca¹, Dr. Michael Koller¹
¹STCS Data Center/University Hospital Basel, Basel, Switzerland

Poster presentations

- P 28** **Renal arteriovenous fistula in a renal transplant recipient: a case report and literature review**
Dr. Justine Schwing¹, Dr. Arthur Piveteau², Dr. Thomas Hernandez³, Prof. Pierre-Yves Martin³, Dr. Karine Hadaya⁴
¹ Geneva University Hospital, Internal Medicine, Geneva, Switzerland, ² Geneva University Hospitals, Radiology, Geneva, Switzerland, ³ Geneva University Hospitals, Nephrology, Geneva, Switzerland, ⁴ Geneva University Hospitals, Nephrology and Transplantation, Geneva, Switzerland
- P 29** **Current state of renal transplant patients in a southern area of Algeria**
Dr. Messaoud Hadj Mohammed¹
¹ Dr TIRICHINE Hospital of Ghardaia, Ghardaia, Algeria

Clinical Nephrology / Hypertension / Mineral / Electrolytes

- P 30** **Protective effect of magnesium supplementation against kidney fibrosis (NCCR Kidney.CH project)**
Dr. Delphine Lambert¹, Dr. Stefan Rudloff¹, Prof. Uyen Huynh-Do¹
¹ Department of Nephrology and Hypertension, Inselspital, and Department for BioMedical Research, University of Bern, Bern, Switzerland
- P 31** **Familial anti-GBM disease associated with a deletion in the COL4A3 gene: a potential clue to etiology**
Dr. Harald Seeger¹, Dr. Vadim Pedchenko², Prof. Carsten Bergmann³, Dr. Ariana Gaspert⁴, Dr. Sergey Budko², Prof. Johan M. Lorenzen¹, Prof. Rudolf P. Wüthrich¹, Prof. Billy Hudson², Dr. Kistler Andreas⁵
¹ University Hospital of Zurich, Zurich, Switzerland, ² Vanderbilt University Medical Center, Nashville, TN, USA, ³ Bioscientia Center for Human Genetics, Ingelheim, Germany, ⁴ University Hospital of Zürich, Institute of Pathology and Molecular Pathology, Zurich, Switzerland, ⁵ Frauenfeld Cantonal Hospital, Frauenfeld, Switzerland

Poster presentations

- P 32** **NOSTONE Trial: Randomized double-blind placebo-controlled trial assessing the efficacy of standard and low dose hydrochlorothiazide treatment in the recurrence prevention of calcareous nephrolithiasis**
Dr. Patrizia Amico¹, Dr. Giulia Bedino², Prof. Olivier Bonny³, Dr. Florian Buchkremer⁴, Dr. Rosaria Del Giorno⁵, Dr. Thomas Hernandez⁶, Dr. Nasser Dhayat⁷, Dr. Nicolas Faller⁷, Prof. Daniel Fuster⁷, Prof. Gabutti Luca⁵, Dr. Carina Hüsler⁸, Dr. Irene Koneth⁸, Prof. Michael Mayr⁹, Dr. Nilufar Mohebbi¹⁰, Dr. Urs Odermatt¹¹, Dr. Lisa Pellegrini², Dr. Alexander Ritter¹⁰, Dr. Beat Roth⁷, Dr. Carlo Schönholzer², Dr. Catherine Stoermann Chopard¹², **Dr. Luca Tamò¹³**, Prof. Daniel Teta¹⁴, Dr. Sven Trelle¹³, Dr. Reto Venzin¹⁵
¹ Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland, ² EOC Lugano, Lugano, Switzerland, ³ CHUV, Lausanne, Switzerland, ⁴ Kantonsspital Aarau, Aarau, Switzerland, ⁵ EOC Bellinzona, Bellinzona, Switzerland, ⁶ HUG, Geneva, Switzerland, ⁷ Inselspital Bern, Bern University Hospital, University of Bern, Switzerland, ⁸ Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁹ University Hospital Basel, Basel, Switzerland, ¹⁰ University Hospital of Zurich, Zurich, Switzerland, ¹¹ Kantonsspital Luzern, Luzern, Switzerland, ¹² University Hospitals of Geneva, department of Nephrology, Geneva, Switzerland, ¹³ CTU Bern, Bern, Switzerland, ¹⁴ Kantonsspital Valais, Sion, Switzerland, ¹⁵ Kantonsspital Graubünden, Chur, Switzerland
- P 33** **The association between zinc and blood pressure – Preliminary data from a population based study**
Dr. Nasser Dhayat¹, Dr. Jean-Pierre Ghobril², Dr. Belen Ponte³, Dr. Menno Pruijm⁴, Dr. Daniel Ackermann¹, Dr. Sandrine Estoppey Younes², Prof. Idris Guessous⁵, Dr. Georg Ehret⁶, Prof. Aurelien Thomas⁷, Prof. Pierre-Yves Martin³, Prof. Michel Burnier⁴, Prof. Bruno Vogt¹, Prof. Murielle Bochud²
¹ Department of Nephrology and Hypertension and Department of Clinical Research, Inselspital, Bern University Hospital, University of Bern, Switzerland, ² Institute of Social and Preventive Medicine, University Hospital of Lausanne, Lausanne, Switzerland, ³ Nephrology Service, Department of Specialties of Internal Medicine, University Hospital of Geneva, Geneva, Switzerland, ⁴ Nephrology Service, University Hospital of Lausanne, Lausanne, Switzerland, ⁵ Division of Primary Care Medicine, University Hospital of Geneva, Geneva, Switzerland, ⁶ Cardiology Service, Department of Specialties of Internal Medicine, University Hospital of Geneva, Geneva, Switzerland, ⁷ Unit of Toxicology, CURML, Lausanne University Hospital, Geneva University Hospitals, Lausanne and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland

Poster presentations

- P 34** **Effect of bariatric surgery-induced weight loss on blood pressure, renal function, electrolytes urinary excretion and hormones : a single center 12 months follow-up**
Dr. Maxime Berney¹
¹Service of nephrology, Lausanne University Hospital, Lausanne, Switzerland
- P 35** **Renal handling of Zinc in a cohort of chronic kidney disease patients as compared to normo-and hypertensive controls with preserved renal function**
 Dr. Katerina Damianaki¹, Mr. Joao Miguel Lourenco², Dr. Philippe Braconier³, Mr. Jean-Pierre Ghobril⁴, Prof. Olivier Devuyst⁵, Prof. Michel Burnier⁶, Prof. Murielle Bochud⁴, Prof. Aurelien Thomas⁷, **Dr. Menno Pruijm¹**
¹CHUV, Lausanne, Switzerland, ²Service of Nephrology and Hypertension, University Hospital of Lausanne, Lausanne, Switzerland, ³Hôpital de la Providence, Neuchâtel, Switzerland, ⁴CHUV, IUMSP, Lausanne, Switzerland, ⁵University Hospital of Zurich, Zurich, Switzerland, ⁶Service of nephrology, Lausanne University Hospital, Lausanne, Switzerland, ⁷CHUV, CUMRL, Lausanne, Switzerland
- P 36** **Renal Tuberculosis Wake-up Call : A Case Report**
Dr. Claudia Ferrier¹, Dr. Alessia Regusci¹, Dr. Bruno Naccini², Dr. Oliver Passera², Dr. Raffaella Pingitore³, Prof. Bruno Vogt⁴
¹Nefrocentro and Clinica Moncucco Lugano, Lugano, Switzerland, ²Clinica Moncucco Lugano, Lugano, Switzerland, ³Clinica St. Anna Lugano, Lugano, Switzerland, ⁴University Hospital Berne, Berne, Switzerland
- P 37** **The Bern ADPKD registry**
Dr. Nasser Dhayat¹, Dr. Manuel Anderegg¹, Dr. Mariam Semmo¹, Prof. Uyen Huynh-Do¹, Prof. Bruno Vogt¹, Prof. Daniel Fuster¹
¹Inselspital Bern, Bern University Hospital, University of Bern, Switzerland

Poster presentations

- P 38** **systemic lupus erythematosus in male patients**
Ms. Jelena Mihailovic¹, Dr. Camillo Ribi², Prof. Carlo Chizzolini³, Prof. Marten Trendelenburg⁴, Prof. Johannes Von Kempis⁵, Dr. Suzan Dahdal¹, Prof. Uyen Huynh-Do¹
¹Department of Nephrology and Hypertension Inselspital, University Hospital, Bern, Switzerland, ²Division of Clinical Immunology and Allergy, University Hospital Lausanne, Lausanne, Switzerland, ³Division of Clinical Immunology and Allergy, Department of Internal Medicine Specialties, University Hospital and School of Medicine, Geneva, Switzerland, ⁴Division of Internal Medicine and Clinical Immunology Laboratory, Department of Biomedicine, University Hospital Basel, Basel, Switzerland, ⁵Division of Rheumatology and Immunology, Department of Internal Medicine, Kantonsspital St Gallen, St Gallen, Switzerland
- P 39** **Primary Hyperoxaluria (PH): Type 1, 2, 3 or none?**
Dr. Anika Ménétrey¹, Dr. Nicolai Stahr¹, Dr. Benno Rothlisberger², Prof. Thomas Neuhaus¹
¹Kinderspital Luzern, Luzern, Switzerland, ²Kantonsspital Aarau, Aarau, Switzerland
- P 40** **Atypical Hemolytic-Uremic Syndrome (aHUS) in Armenian children : cluster of DEAP HUS?**
Dr. Emma Shahinyan¹, Dr. Helen Nazaryan¹, Dr. Milena Voskanyan², Prof. Zoltán Prohászka³, Prof. Markus Kemper⁴, Prof. Carsten Bergmann⁵, Prof. Ashot Sarkissian²
¹Department of Nephrology, Arabkir Medical Centre, Yerevan, Armenia, ²Department of Pediatrics, Yerevan State Medical University, Yerevan, Armenia, ³Third Department of Internal Medicine, Semmelweis University, Budapest, Hungary, ⁴Department of Pediatrics, Asklepios Nord-Heidelberg, Hamburg, Germany, ⁵Bioscientia Center for Human Genetics, Ingelheim, Germany
- P 41** **Characteristics and outcome of IgA nephropathy in Switzerland-a single center perspective**
Mr. Danny Thieny Taing¹, Prof. Bruno Vogt², Dr. Laila-Yasmin Mani²
¹University of Bern, ²Inselspital Bern, Bern University Hospital, University of Bern, Switzerland

Poster presentations

- P 42** **Red blood cell volume may not always be decreased in anemic chronic kidney disease patients**
 Prof. Carsten Lundby¹, Dr. Belen Ponte², Dr. Paul Robach³, **Prof. Sophie De Seigneux²**
¹Rigshospitalet - Finsencentret, Blegdamsvej 9, 2100 København, Denmark, ²University Hospital of Geneva, Geneva, Switzerland, ³Ecole Nationale des Sports de Montagne, site de l'Ecole Nationale de Ski et d'alpinisme, Chamonix, France
- P 43** **Chronic kidney disease and therapeutic patient education program**
Dr. Anne Dufey Teso¹, Mrs. Pascale Lefuel¹, Prof. Alain Goly¹, Prof. Sophie De Seigneux¹, Prof. Pierre-Yves Martin¹
¹University Hospital of Geneva, Geneva, Switzerland
- P 44** **attitudes and practices among swiss nephrologists regarding end-of-life care: is there a change in the past 12 years? a national survey**
Dr. Sandra Eckstein¹, Prof. Michael Mayr¹, Dr. Isabelle Binet², Prof. Jürg Steiger³, Prof. Alexander Kiss⁴
¹University Hospital Basel, Basel, Switzerland, ²Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland, ⁴University hospital Basel, Basel Switzerland
- P 45** **Systemic primary Sjögren's Syndrome with multi-organ involvement - a rare case**
 Dr. Emmanuelle Landmann¹, Dr. Helmut Hopfer², **Dr. Katrin König¹**
¹Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland, ²Institute for Pathology, University Hospital Basel, Basel, Switzerland
- P 46** **Using the CKD-EPI formula for drug dose adjustments in patients with impaired kidney function - a graphical analysis**
Dr. Florian Buchkremer¹, Prof. Andreas Bock¹, Prof. Stephan Segerer¹
¹Division of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Aarau, Switzerland

Poster presentations

- P 47** **Liquid intake in the Swiss Kidney Stone Cohort**
 Ms. Nadia Ammor¹, Ms. Tanja Haeusermann², Prof. Daniel Fuster³, Dr. Nasser Dhayat³, Dr. Nilufar Mohebbi⁴, Dr. Harald Seeger⁴, Dr. Thomas Hernandez⁵, Dr. Catherine Stoermann Chopard⁶, Dr. Florian Buchkremer⁷, Prof. Stephan Segerer⁸, Dr. Wuerzner Grégoire¹, Dr. Kim Min Jeong⁹, Prof. Michael Mayr¹⁰, Dr. Beat Roth³, Prof. Carsten Wagner¹¹, **Prof. Olivier Bonny¹²**
¹Service of nephrology, Lausanne University Hospital, Lausanne, Switzerland, ²Swiss Kidney Stone Cohort, NCCR Kidney.CH, Bern, Switzerland, ³Inselspital Bern, Bern University Hospital, University of Bern, Switzerland, ⁴University Hospital of Zurich, Zurich, Switzerland, ⁵HUG, Geneva, Switzerland, ⁶University Hospitals of Geneva, department of Nephrology, Geneva, Switzerland, ⁷Kantonsspital Aarau, Aarau, Switzerland, ⁸Division of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Aarau, Switzerland, ⁹Kantonsspital St. Gallen, St. Gallen, Switzerland, ¹⁰University Hospital Basel, Basel, Switzerland, ¹¹University of Zurich, Institute of Physiology, Zurich, Switzerland, ¹²CHUV and University of Lausanne, Lausanne, Switzerland
- P 48** **A young woman with primary membranous nephritis complicated by aHUS: is there a link?**
 Dr. Hans-Rudolf Rätz¹, **Dr. Susanne Winkler¹**, Dr. Nilufar Mohebbi², Dr. Helmuth Hopfer³, Dr. Ariana Gaspert⁴, Dr. Harald Seeger²
¹Kantonsspital Baden, Institute for Nephrology and Dialysis, Baden, Switzerland, ²University Hospital of Zurich, Clinic for Nephrology, Zürich, Switzerland, ³University Hospital Basel, Institute for Pathology, Basel, Switzerland, ⁴University Hospital of Zürich, Institute for Pathology and Molecular Pathology, Zürich, Switzerland
- P 49** **Lower belly pain, flu-like symptoms and nephrotic syndrome**
Mr. Örs Sajthy¹, Dr. Marco Miozzari¹
¹Spitäler Schaffhausen, department of nephrology, Schaffhausen, Switzerland

Poster presentations

- P 50** **Too much of a good thing: Three cases of vitamin D intoxication due to lifestyle use**
Mr. Laurent Haas¹, Prof. Andreas Bock², Prof. Stephan Segerer³
¹Kantonsspital Aarau, Aarau, Switzerland, ²Division of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Switzerland, ³Division of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Aarau, Switzerland
- P 51** **Successful management of pembrulizumab-induced acute interstitial nephritis without discontinuation of the oncologic drug in a patient with disseminated melanoma**
Dr. Alessandra Molteni¹, Dr. Eugenia Zuliani², Dr. Antonello Calderoni³, Dr. Giulia Bedino¹, Dr. Helmut Hopfer⁴, Dr. Davide Giunzioni¹, Dr. Marianna De Francesco¹, Dr. Jennifer Scotti Gerber¹, Dr. Carlo Schoenholzer¹
¹Department of Nephrology, Ospedale Regionale di Lugano, Lugano, Switzerland, ²Studio Medico Dr.med Eugenia Zuliani, Lugano, Switzerland, ³Oncologia Varini, Calderoni, Christinat, Lugano, Switzerland, ⁴Institute for Pathology, University Hospital Basel, Basel, Switzerland
- P 52** **Acute Renal Failure in a patient with Rivaroxaban-Induced Hypersensitivity Syndrome: a case report and review of the literature**
Dr. Gisela Marcelino¹, Dr. Ould Maouloud Hemett², Dr. Eric Descombes¹
¹Service of nephrology, HFR Fribourg, Fribourg, Switzerland, ²Service of nephrology, HFR Fribourg, Fribourg, Switzerland
- P 53** **Plasma angiotensins in hypertensive patients screened for aldosteronism**
Dr. Jürgen Bohlender¹, Dr. Marko Poglitsch², Prof. Bruno Vogt³, Prof. Manuel Haschke¹
¹Department of Clinical Pharmacology, University Clinic for General Internal Medicine, Inselspital, University of Bern, Bern, Switzerland, ²Attoquant Diagnostics Inc., Vienna, Austria, ³Department of Nephrology and Hypertension Inselspital, University Hospital, Bern, Switzerland
- P 54** **Rhabdomyolysis-induced acute renal injury following concomitant use of genvoya® (evg/cobi/etc/taf) and simvastatine; a case report**
Dr. Rita Godinho¹, Dr. Serge Bugnon¹, Dr. Terezija Gracin¹, Dr. James TATAW¹
¹Hopital du Jura bernois SA, Moutier, Switzerland

Poster presentations

- P 55** **Evaluation of sFlt-1/PIGF Ratio for Predicting and Improving Clinical Management of Pre-eclampsia in lupus nephritis: a single case experience in CHUV**
Dr. Mariangela Ventresca¹, Prof. Francois Spertini², Dr. David Desseauve³, Dr. Helene Legardeur³, Dr. Sebastien Kissling¹, Dr. Floriane Beaud¹, Dr. Nora Schwotzer¹, Dr. Samuel Rotman⁴, Dr. Tsai Chun-yi⁴, Dr. Wuerzner Grégoire¹, Dr. Olivier Phan¹
¹Service of nephrology, Lausanne University Hospital, Lausanne, Switzerland, ²Service of immunology and allergology, Lausanne University Hospital, Lausanne, Switzerland, ³Service of gynecology, Lausanne University Hospital, Lausanne, Switzerland, ⁴Service of pathology, Lausanne University Hospital, Lausanne, Switzerland
- P 56** **devastating cefepime-induced nephrotoxicity**
Mr. Davide Spica¹, Mrs. Sara De Marchi¹, Dr. Patrizia Amico¹, Dr. Helmut Hopfer²
¹Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland, ²Institute for Pathology, University Hospital Basel, Basel, Switzerland
- P 57** **A case of crystal nephropathy after amoxicillin administration**
Dr. Nikolaos Drivakos¹, Prof. Michael Dickenmann², Dr. Mira Hintermann³
¹Department of Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland, ²Clinic for Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland, ³Department of Transplantation Immunology and Nephrology, University Hospital Basel, Switzerland
- P 58** **Angioplasty with stenting in acute coronary syndromes with very low contrast volume (<30ml) using 6F Cordis diagnostic catheters and improved cardiovascular and renal outcomes**
Prof. Mark Christopher Arokiaraj¹
¹Pondicherry Institute of medical sciences, Pondichery, India

Poster presentations

- P 59** **Prevalence of cardio renal risk factors in population-Baseline data of a selected rural community in Bangladesh (BAN Ca-Re study)**
Dr. MM Iqbal¹, Prof. Maa Chowdhury², Prof. Sk Banerjee³, Prof. S Iqbal⁴, Prof. S Islam³, Prof. Mz Hassan⁵, Prof. Ms Hassan⁶, Prof. Sr Choudhury⁷, Dr. Rm Hossain³, Prof. Mn Islam⁶, Prof. Mi Arslan³, Dr. Mza Bhuiyan⁸
¹SSMC & Mitford Hospital, Dhaka, Bangladesh, ²NIKDU, Dhaka, Bangladesh, ³BSMMU, Dhaka, Bangladesh, ⁴BIRDEM, Dhaka, Bangladesh, ⁵BUHS, Dhaka, Bangladesh, ⁶Asgar Ali Hospital, Dhaka, Bangladesh, ⁷NHFRI, Dhaka, Bangladesh, ⁸lab.de Genetique Molecula, Lausanne, Switzerland

Hemodialysis / Peritoneal Dialysis

- P 60** **Outpatient post-dialysis Daptomycin prescription in an anephric hemodialysis (HD) patient: how much?**
Dr. Marie Baeriswyl¹, Dr. Ould Maouloud Hemett¹, Dr. Veronique Erard², Dr. Eric Descombes³
¹Service of nephrology, HFR Fribourg, Fribourg, Switzerland, ²Service of infectious diseases, HFR Fribourg, Fribourg, Switzerland, ³Service of nephrology, HFR Fribourg, Fribourg, Switzerland
- P 61** **Creation of the Renal Access Dialysis Registry (RADY): difficulties and initial results**
Dr. Hilary Riva¹, Dr. Olivier Giannini², Ms. Meltem Yenigün³, Mr. Alan Valnegri³, Dr. Silvio Pianca⁴, Dr. Lorenzo Berwert⁵, Dr. Giorgia Bianchi⁶, Dr. Giuseppe Bonforte¹
¹Service of Nephrology, Ente Ospedaliero Cantonale (EOC), Ospedale Regionale di Mendrisio, Mendrisio, Switzerland, ²Department of Internal Medicine and Service of Nephrology, Ente Ospedaliero Cantonale (EOC), Ospedale Regionale di Mendrisio, Mendrisio, Switzerland, ³Support Area, Ente-Ospedaliero Cantonale (EOC), General Direction Bellinzona, Bellinzona, Switzerland, ⁴Service of Nephrology, Ente Ospedaliero Cantonale (EOC), Ospedale Regionale di Lugano, Lugano, Switzerland, ⁵Service of Nephrology, Ente Ospedaliero Cantonale (EOC), Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland, ⁶Service of Nephrology, Ente Ospedaliero Cantonale (EOC), Ospedale Regionale di Locarno, Locarno, Switzerland

Poster presentations

- P 62** **T50 and fetuin modification by dialysis initiation**
Dr. Belen Ponte¹, Dr. Menno Pruijm², Dr. Thomas Hernandez³, Dr. Andreas Pasch⁴, Prof. Pierre-Yves Martin¹, **Prof. Sophie De Seigneux**¹
¹University Hospital of Geneva, Geneva, Switzerland, ²CHUV, Lausanne, Switzerland, ³HUG, Geneva, Switzerland, ⁴Calciscon, Nidau, Switzerland
- P 63** **The Performance of Saliva Uric Acid Reduction Ratio as a Measure of Dialysis efficiency in Maintenance Hemodialysis**
Prof. Gloria Ashuntantang¹, Dr. Brunhilda Nkengafack¹, Dr. Karine Mba¹, Dr. Denis Georges Teuwafeu², Dr. Maimouna Mahamat¹, Dr. James TATAW³, Dr. Aristide Nono¹, Dr. Karla Acha Mukwelle¹
¹Yaounde General Hospital, Cameroon, ²Buea Regional hospital, Buea, Cameroon, ³Hopital du Jura bernois SA, Moutier, Switzerland
- P 64** **A retrospective case series of vascular graft materials for hemodialysis**
Dr. Louisa Gerhardt¹, Prof. Andreas Bock², Dr. Regula Marti³, Prof. Stephan Segerer¹
¹Division of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Aarau, Switzerland, ²Division of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Switzerland, ³Division of Vascular Surgery, Kantonsspital Aarau, Switzerland
- P 65** **The role of intraoperative continuous renal replacement therapy in severe acidosis – A single center experience**
Dr. Jennifer Scotti Gerber¹, Dr. Giulia Bedino¹, Dr. Davide Giunzioni¹, Dr. Marianna De Francesco², Dr. Alessio Acuzio¹, Prof. Paolo Merlani¹, Dr. Carlo Schoenholzer¹
¹Ospedale Regionale di Lugano, Lugano, Switzerland, ²Department of Nephrology, Ospedale Regionale di Lugano, Lugano, Switzerland
- P 66** **Survival on dialysis: Switzerland in comparison with other countries**
Ms. Rebecca Winzeler¹, Prof. Ambühl Patrice¹
¹Stadtsipital Waid, Zurich, Switzerland

Poster presentations

- P 67** **Zinc serum concentration in hemodialysis patients with and without zinc supplementation**
Dr. Samuel Gehrke¹, Dr. Robert Kalicki¹, Dr. Benoit Fellay², Dr. Ould Maouloud Hemett³, Dr. Jean-luc Magnin², Dr. Eric Descombes¹
¹Service of nephrology, HFR Fribourg, Fribourg, Switzerland, ²Central Laboratory, HFR Fribourg, Fribourg, Switzerland, ³Service of nephrology, HFR Fribourg, Fribourg, Switzerland
- P 68** **Survival in Swiss diabetic patients on dialysis: A follow-up**
Ms. Rebecca Winzeler¹, Prof. Ambühl Patrice¹
¹Stadtspital Waid, Zurich, Zurich, Switzerland
- P 69** **Effectiveness of thoracoscopy in treating pleural effusion in peritoneal dialysis**
Dr. Valérie Jotterand Drepper¹, Dr. Catherine Stoermann Chopard¹, Prof. Pierre-Yves Martin¹, Dr. Wolfram Karenovics²
¹University Hospitals of Geneva, department of Nephrology, Geneva, Switzerland, ²University Hospitals of Geneva, Department of Thoracic and Endocrine Surgery, Geneva, Switzerland
- P 70** **The Effects of regular physical exercise on nutrition and inflammation in patients on maintenance haemodialysis in Cameroon. A non-randomized single-arm clinical trial**
Prof. Gloria Ashuntantang¹, Dr. Ndumbe Kinge¹, Dr. Marcel Azabji², Dr. James TATAW³, Dr. Kamgang Willy¹, Dr. Maimouna Mahamat¹, Dr. Aristide Nono¹, Dr. Karla Acha Mukwelle¹, Prof. Julius Oben²
¹Yaounde General Hospital, Cameroon, ²University of Yaounde I, Cameroon, ³Hopital du Jura bernois SA, Moutier, Switzerland
- P 71** **End Stage Renal Disease in pediatric and adolescent population in a southern area of algeria**
Dr. Messaoud Hadj Mohammed¹
¹Dr TIRICHINE Brahim Hospital, Blida, Algeria

Poster presentations

- P 72** **aerococcus sanguinicola - a rare cause of pd -related peritonitis**
Dr. Stephanie Damm¹, Prof. Stephan Segerer¹, Dr. Christoph Fux², Dr. Lukas Gerber³
¹Division of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Switzerland, ²Departement of Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Switzerland, ³Division of Nephrology, Dialysis and Transplantation, Kantonsspital Aarau, Switzerland
- P 73** **Low copeptin (CTproAVP) levels in patients with intradialytic hypotension**
Dr. Berfu Korucu¹, Dr. Ozant Helvacı¹, Dr. Hasan Yeter¹, Dr. Burak Ozbas¹, Dr. Deniz Yuce², Dr. Sehri Elbeg³, Prof. Ulver Derici¹
¹Gazi University Faculty of Medicine, Department of Nephrology, Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Preventive Oncology, Ankara, Turkey, ³Gazi University Faculty of Medicine, Department of Biochemistry, Ankara, Turkey


Notes

[illegible]

Notes

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

Plan of exhibition



Exhibitors

Company	Booth
AIRG	28
Alexion Pharma GmbH	10
Amgen Switzerland AG	3
Amgen Switzerland AG	4
Astellas Pharma AG	14
B. Braun Medical AG	30
Baxter AG	12
Bracco Suisse SA	2
D.Med Homecare	5
Forni medical gmbh	17
Fresenius Medical Care (Schweiz) AG	20
Laboratorium Dr G. Bichsel AG	18
MCM MEDSYS AG	31
Mitsubishi Tanabe Pharma GmbH	25
Mundipharma Medical Company	21
Neovii Pharmaceuticals AG	7
Novartis Pharma Schweiz AG	26
Otsuka Pharmaceutical (Switzerland) GmbH	15
Peripal AG	22
Recordati AG	11
Roche Pharma (Schweiz) AG	8
Salmon Pharma GmbH	16
Samsung Meditron	1
sanofi-aventis (schweiz) ag	9
Schweizer Dialyseregister	6
Shire Switzerland GmbH	27
theramed ag	13
Vifor SA	19
Vifor SA	32
VNPS	29

Speakers / Moderators

AMBÜHL Patrice, Zurich
 AMICO Patrizia, Basel
 ARAMPATZIS Yoannis Spyridon, Bern
 AUBERT Olivier, Paris (FR)
 BEHAGHEL Ghislaine, Lausanne
 BINET Isabelle, St.Gallen
 BOCHUD Murielle, Lausanne
 BOCK Andreas, Aarau
 BONNY Olivier, Lausanne
 BOURQUIN Vincent, Geneva
 BUCHER Christian, St. Gallen
 BURKHALTER Felix, Liestal
 BURNIER Michel, Lausanne
 CIPPÀ Pietro, Lugano
 CIUTTO Lorella, Sion
 DE SEIGNEUX Sophie, Geneva
 DESNICK Robert J., Mount Sinai (US)
 DEVUYST Olivier, Zurich
 DIETRICH Ursula, Bern
 DRÜKE Tilman B., Villejuif/Paris (FR)
 ERNANDEZ Thomas, Geneva
 FEEHALLY John, Leicester (UK)
 FERAILLE Eric, Geneva
 FUSTER Daniel, Bern
 GABUTTI Luca, Bellinzona
 GENTON Laurence, Geneva
 GEORGALIS Argyrios, Basel
 GOLSHAYAN Déla, Lausanne
 GRIGNOLI Nicola, Mendrisio
 GUIGNARD Jean-Pierre, Lausanne
 HEIGL Franziska, Bern
 HELT Ute, Zurich
 HERTNER Daniel, Schwyz
 HERZIG Sabine, Bern
 HUBER Tobias, Hamburg (DE)

HUYNH-DO Uyen, Bern
 ISELLA Giovanni, Lugano
 KIM Min Jeong, Aarau
 KISTLER Andreas, Frauenfeld
 KÖNIG Irma, Bellinzona
 KÖTTGEN Anna, Freiburg (DE)
 LAZAREVIC Predrag, Bellinzona
 MARTIN Pierre-Yves, Geneva
 MAUTHNER Oliver, Basel
 MOHAUPT Markus, Bern
 MURER Heini, Zurich
 NEUHAUS Thomas J., Lucerne
 PASCUAL Manuel, Lausanne
 PHAN Olivier, Lausanne
 PONTE Belen, Geneva
 PRUIJM Menno, Lausanne
 RIBI Camillo, Lausanne
 ROSSIER Bernard, Lausanne
 ROSSIGNOL Patrick, Nancy (FR)
 SAUDAN Patrick, Geneva
 SCHAUB Stefan, Basel
 SCHÖNBÄCHLER Claudia, Zurich
 SCHWARZKOPF Ann-Kathrin, Bern
 SEGERER Stephan, Aarau
 SIDLER Daniel, Bern
 STEIGER Jürg, Basel
 STUDER Claudia, Zurich
 TARTAGLIA Francesca, Bellinzona
 TETA Daniel, Sion
 UEHLINGER Dominik, Bern
 VOGT Bruno, Bern
 WAGNER Carsten, Zurich
 WILSON Patrick, Delémont
 WUERZNER Grégoire, Lausanne
 WÜTHRICH Rudolf. P., Zurich

Association

Association pour l'Information et la Recherche sur les maladies rénales Génétiques (AIRG)



Verband Nierenpatienten Schweiz (VNPS)

Sponsored in alphabetical order

Symposia



Amgen Switzerland AG

Parallel Symposium

Friday, December 7, 2018 – 9.45-10.30 / Room B



Astellas Pharma AG

Exclusive Symposium

Thursday, December 6, 2018 – 15.30-16.15 / Room A



Sanofi-aventis (Switzerland) SA

Exclusive symposium

Friday, December 7, 2018 – 12.15-13.15 / Room A



Vifor SA

Exclusive Symposium

Thursday, December 6, 2018 – 12.30-13.15 / Room A

Advertisement

Mundipharma

Otsuka Pharmaceutical (Switzerland) GmbH

Sanofi-aventis (Switzerland) AG

Vifor SA

Kind thanks to all our sponsors

ALEXION

AMGEN®

astellas

B | BRAUN
SHARING EXPERTISE

Baxter

BRACCO
LIFE FROM INSIDE

D.med
homecare

fm forni medical gmbh

FRESENIUS
MEDICAL CARE

bichsel

MCM MEDSYS
Together to excellence

Mitsubishi Tanabe Pharma GmbH

mundi pharma

neovii

Kind thanks to all our sponsors

NOVARTIS

Otsuka

peripal

RECORDATI
GROUP

Roche

Salmon Pharma
Ein Unternehmen der

MEDICE

SAMSUNG
SAMSUNG MEDISON
Authorized distributor for Samsung Medison in Switzerland

MediTron

SANDOZ A Novartis
Division

SANOFI

SANOFI GENZYME

+srrqap
swiss renal registry and quality assessment program

Shire

theramed ag
medizinprodukte

VIFOR
PHARMA

Save the date: SGN-SSN congress 2019

We would like to invite you to the

51st Annual Meeting of the Swiss Society of Nephrology SGN-SSN
on **December 5-6, 2019** – Congress Centre Kursaal Interlaken



Please save the dates of December 5-6, 2019!

We look forward to welcoming you in Interlaken next year!



www.swissnephrology.ch

Schweizerische Gesellschaft für Nephrologie
Société Suisse de Néphrologie
Società Svizzera di Nefrologia



DIE NIERE# MACHT DEN UNTERSCHIED

FIRST
IN CLASS[®]

BEI TYP-2-DIABETIKERN¹

SENKUNG VON:

- HbA_{1c}¹

ZUSATZEFFEKTE, REDUKTION VON:

- systolischem Blutdruck^{+,1}
- Körpergewicht^{+,1}

KASSENZULÄSSIG²

Invokana[®]
Canagliflozin Tabletten

Vokanamet[®]
Canagliflozin/Metformin HCl

SGLT-2-HEMMER BEI DIABETES MELLITUS TYP 2

primärer Wirkort der SGLT2-Hemmer \$ bezüglich Markteinführung in der Schweiz + Invokana ist nicht indiziert zur Behandlung von Hypertonie und Übergewicht. Gewichtsreduktion und Blutdrucksenkung sind Zusatzeffekte. * gemäss Indikation, siehe Limitatio 1. Fachinformation Invokana[®]/Vokanamet[®] (<http://www.swissmedinfo.ch>). 2. <http://www.spezialistenliste.ch>.

Invokana[®] (Canagliflozin), **Vokanamet[®]** (Canagliflozin, Metforminhydrochlorid) I: Invokana[®]: zur Behandlung des Diabetes mellitus Typ 2 bei Erwachsenen, wenn durch Diät und gesteigerte körperliche Aktivität keine ausreichende Kontrolle der Glykämie erreicht wird. Als Monotherapie bei Patienten, die nicht mit Metformin behandelt werden können. In Kombination mit Metformin, mit einem Sulfonylharnstoff (mit oder ohne Metformin) oder mit Insulin (mit oder ohne Metformin), wenn mit diesen Behandlungen keine ausreichende Kontrolle der Glykämie erreicht wird. Vokanamet[®]: bei Patienten, die mit der maximal tolerierten Dosis Metformin unzureichend eingestellt sind; bei Patienten, die mit der maximal tolerierten Dosis Metformin zusammen mit einem Sulfonylharnstoff oder mit Insulin unzureichend eingestellt sind; bei Patienten, die bereits mit Canagliflozin und Metformin als separate Tabletten behandelt werden. D: Invokana[®]: Die empfohlene Dosis beträgt 100 mg einmal täglich. Bei Bedarf für stärkere glykämische Kontrolle: Dosiserhöhung auf 300 mg, sofern ein geringes Risiko für unerwünschte Wirkungen im Zusammenhang mit einem reduzierten intravasculären Volumen und einer eGFR ≥ 60 ml/min/1,73 m² besteht. Vokanamet[®]: Bei unzureichender Einstellung mit Metformin allein: 50 mg Canagliflozin zweimal täglich zusammen mit der bisherigen Dosis Metformin oder der nächsten therapeutisch angemessenen Dosis von Metformin. Bei Bedarf für stärkere glykämische Kontrolle: Dosiserhöhung auf 150 mg Canagliflozin zweimal täglich, sofern 50 mg Canagliflozin zweimal täglich toleriert werden und ein niedriges Risiko für reduziertes intravasculäres Volumen und eine eGFR ≥ 60 ml/min/1,73 m² besteht. Bei Umstellung von separaten Tabletten von Canagliflozin und Metformin: bisherige Tagesgesamtosis von Canagliflozin und Metformin oder die nächste therapeutisch angemessene Metformindosis. Kt: Überempfindlichkeit gegen Canagliflozin oder einem der Hilfsstoffe. Vokanamet[®]: Überempfindlichkeit gegenüber Metformin; diabetische Ketoazidose, diabetisches Präkoma; Nierenfunktionsstörung (eGFR < 60 ml/min/1,73 m² oder Kreatinin-Clearance [CrCl] < 60 ml/min); akute Erkrankungen, welche die Nierenfunktion beeinflussen können; akute oder chronische Erkrankungen, die eine Gewebeschädigung verursachen können; Leberinsuffizienz, akute Alkoholvergiftung, Alkoholisierung. Vt: Invokana[®], Vokanamet[®] sollte nicht bei Patienten mit Diabetes mellitus Typ 1 und zur Behandlung einer diabetischen Ketoazidose angewendet werden. Bei Anzeichen einer Azidose sollte eine diabetische Ketoazidose (DKA) auch bei Blutglukosespiegeln unter 13,9 mmol/l in Erwägung gezogen werden, bei bestätigter Diagnose sofort Behandlung beginnen. Vorsicht geboten bei Risiko für eine Volumendepletion, ischämischer Herzkrankheit oder zerebrovaskulären Erkrankungen, älteren Patienten ≥ 75 Jahre oder gleichzeitiger Gabe von Kalium-sparenden Diuretika (Hyperkaliämie), Arzneimitteln, die auf das Renin-Angiotensin-Aldosteron-System zugreifen. Bei gleichzeitiger Gabe von Insulin oder einem Insulin-Sekretagogum muss aufgrund des Hypoglykämie-Risikos eine Dosisreduktion des Insulins oder des Insulin-Sekretagogums in Erwägung gezogen werden; Nutzen-Risiko-Abwägung bei rezidivierenden genitalen Pilzinfektionen. Invokana[®]: Wenn die eGFR dauerhaft < 45 ml/min/1,73 m² oder die CrCl < 45 ml/min liegt, sollte Invokana[®] abgesetzt werden; beim Vorliegen einer eGFR < 60 ml/min/1,73 m² oder einer CrCl < 60 ml/min ist zusätzliche Vorsicht geboten, die Nierenfunktion ist regelmässig zu kontrollieren. Vokanamet[®]: bei Verdacht auf Laktatazidose sofortiger Abbruch der Therapie. UAW: Canagliflozin: Hypoglykämie in Kombination mit Insulin oder Sulfonylharnstoffen, Vulvovaginale Candidiasis, Balanitis oder Balanoposthitis, Polyurie oder Pollakisurie, Harnwegsinfekte, Verstopfung, Durst, Dehydrierung, Hypotonie. Nach Markteinführung: diabetische Ketoazidose, anaphylakt. Reaktion, Angiodödem, Niereninsuffizienz (in Zusammenhang mit Volumendepletion), Amputationen an den unteren Gliedmassen Metformin: Gastrointestinale Störungen, Metallgeschmack, erniedrigter Vitamin-B12-Spiegel, Laktatazidose. Weitere UAW siehe FI. IA: Invokana[®]/Vokanamet[®]: führt zu keiner Induktion einer CYP450-Enzymexpression; bei gleichzeitiger Verabreichung von Induktoren der UGT und Arzneimitteltransportsysteme kann die Wirksamkeit von Canagliflozin vermindert sein. Vokanamet[®]: Bei gleichzeitiger Anwendung mit Alkohol kann es zur Verstärkung der blutzuckersenkenden Wirkung von Metformin bis zum hypoglykämischen Koma kommen. Liste siehe FI. S5: Die Anwendung sollte während einer Schwangerschaft oder Stillzeit vermieden werden. Packungen: Invokana[®]: Filmtabletten zu 30, 100, Vokanamet[®]: Flaschen zu 60 und 180 (3x60) Filmtabletten. Kassenzulässig. Abgabekst.: B. Ausführliche Informationen: www.swissmedinfo.ch; Zulassungsinhaber: Janssen-Cilag AG, Gubelstrasse 34, 6300 Zug (P4CHMDM0017/0008)

www.mundipharma.ch



RENVELA®

Your partner against hyperphosphatemia¹

Renvela®
Sevelamercarbonat

- ✓ Calcium-free
- ✓ Metal-free*
- ✓ Not absorbed**

Renvela® powder can be premixed with beverage as well as with food[†]

Right from the start.

Renvela®
Sevelamercarbonat

* Active substance without metals or calcium. Sevelamer carbonate is a polymer that is not absorbed in the gastrointestinal tract.

** In a one-year clinical study, no evidence of sevelamer accumulation was shown.

† New possibility of use: as an alternative to water, the powder may be pre-mixed with a small amount of beverage (sparkling or not) or food and consumed within 30 minutes. Do not heat Renvela (e.g., microwave) or add to hot foods or liquids.

Renvela® Film-coated tablets 800 mg and powder 2.4 g. **DS:** Sevelamer carbonate. **I:** Adults. hyperphosphatemia in patients undergoing haemodialysis or peritoneal dialysis and nonhaemodialysis-dependent patients with chronic renal insufficiency and serum phosphorus levels of ≥ 1.78 mmol/L. For use in multiple treatment. **D:** 2.4 g or 4.8 g per day (initial dose) spread over three meals. Average approx. 6 g/day with continuous treatment. Drink suspension within 30 minutes of preparation. **CE:** Hypersensitivity to an active substance, hypophosphatemia, bowel obstruction. **WP:** Children and adolescents under 18 years of age, non-haemodialysis-dependent patients with chronic renal insufficiency and serum phosphorus level < 1.78 mmol/L, patients with dysphagia, swallowing disorders, severe gastrointestinal motility dysfunction (including untreated or severe gastroesophageal reflux or irregular bowel movement), active inflammatory bowel disease, major surgery on the gastrointestinal tract, disphagia, bowel obstruction, ileus/paralytic, reduced absorption of liposoluble vitamins (A, B, E and K), bone deficiency, hyperparathyroidism, metabolic acidosis, parathyroid, simultaneous use of antacid/antacid and antacid/acidic drugs, hypophosphatemia, long-term chronic treatment (> 1 year) with sevelamer, hyperparathyroidism. **IA:** Reduced risk of hypophosphatemia and hypocalcemia levels in transplant patients. Monitor TSH level when administering levothyroxine. Particular caution is required with patients using antiepileptic or antiepileptic drugs. Renvela is not absorbed and can affect the bioavailability of other drugs. These are to be given at least one hour before or three hours after Renvela. **SE:** very common: nausea, vomiting, pain in the upper abdomen, constipation. Frequent: diarrhoea, dyspepsia, flatulence, stomach pain. Pregnancy/Lactation: Do not use unless it is clearly necessary. **P:** Renvela film-coated tab. 800 mg bl. 180 pcs. Renvela powder 2.4 g pouch 60 pcs. **Med. class:** B[†]. **MAH:** Sanofi-Aventis (Switzerland) AG, 1214 Vernier/GE. **Updated:** Film-coated tablets: February 2018; powder: February 2018 (SACH.SEC.18.05.0422). For further specialized information please visit www.swissmedica.ch.

¹ Professional Information Renvela®, www.swissmedica.ch

SANOFI